

Pharmacological Management of Persistent Hostility and Aggression in Persons With Schizophrenia Spectrum Disorders: A Systematic Review

Jeff Victoroff, M.D.
Kerry Coburn, M.A., Ph.D.
Alya Reeve, M.D.
Shirlene Sampson, M.D.
Samuel Shillcutt, Ph.D., Pharm.D.

The incidence of aggressive behaviors is higher among persons with schizophrenia spectrum disorders (SSDs) than among persons without such disorders. This phenomenon represents a risk to the well-being of patients, their families, and society. The authors undertook a systematic review of the English language literature to determine the efficacy of neuropharmacological agents for the management of hostility and aggression among persons with SSDs. The search combined findings from the Medline, EMBASE, and PsycINFO databases. Ninety-two full text articles were identified that reported relevant findings. The American Academy of Neurology criteria were used to determine levels of evidence. Paliperidone-extended release is probably effective for the management of hostility among inpatients with SSDs who have not been preselected for aggression (Level B). Clozapine is possibly more effective than haloperidol for the management of overt aggression and possibly more effective than chlorpromazine for the management of hostility among inpatients with SSDs who have not been preselected for aggression (Level C). Clozapine is

also possibly more effective than olanzapine or haloperidol for reducing aggression among selected physically assaultive inpatients (Level C). Adjunctive propranolol, valproic acid, and famotidine are possibly effective for reducing some aspects of hostility or aggression among inpatients with SSDs (Level C). Paliperidone-extended release currently appears to be the agent for the management of hostility among inpatients with SSDs for which there is the strongest evidence of efficacy.

(The Journal of Neuropsychiatry and Clinical Neurosciences 2014; 26:283–312)

Schizophrenia spectrum disorders (SSDs) are associated with an elevated risk of committing violent acts, especially assaults, or for being convicted for such acts.^{1–9} For example, in a 26-year prospective study of a Finnish birth cohort including 12,058 subjects, persons with schizophrenia exhibited 7.0 times the community rate

Received November 13, 2013; accepted November 13, 2014. From the Dept. of Neurology, University of Southern California Keck School of Medicine, Torrance, Calif. (JV); the Dept. of Psychiatry, Mercer University, Macon, Ga. (KC, AR, S. Shillcutt); and the Mayo Clinic, Rochester, Minn. (S. Sampson). Send correspondence to Dr. Victoroff; e-mail: victorof@usc.edu

Copyright © 2014 American Psychiatric Association

of commission of violent crime.³ In a 44-year retrospective study of a Danish birth cohort of 358,180 persons, the diagnosis of schizophrenia was associated with 4.6 times the rate of arrest for violence among men, and 23.2 times the rate among women.⁵ Some of this excess risk of aggression has been related to premorbid conduct disorder,^{10,11} positive symptoms, especially paranoia,^{12,13} or concomitant antisocial or psychopathic traits^{14–17} with or without concomitant substance abuse.^{2,7,18–23} Moderating factors aside, evidence from 1) studies of violence among psychiatric patients, 2) studies of the prevalence of SSDs among violent persons, or 3) studies of birth or population cohorts all support the conclusion that SSDs are a significant risk factor for interpersonal violence.

This finding is associated with multiple problematic consequences. Violence threatens the lives and well-being both of patients and of others in their immediate social surroundings.²⁴ Violent behavior is associated with non-compliance and complicates treatment.^{6,25} Violence disrupts families that might offer a vital stabilizing force for the patients.²⁶ Violence increases the need for institutionalization, with its attendant costs and restriction of self-determination.⁹ Violence by persons with SSDs contributes to the stigma that biases laypersons against not only all persons with schizophrenia but against all those with mental illness.^{25,27,28} In so far as SSDs occur in roughly 1% of most populations, that subset of persons will contribute to society's net burden of violence. Although the attributable risk is small—estimated to be on the order of 5% of total societal violence^{6,29,30}—SSD-associated violence has been estimated to account for 6%–28% of homicides⁹ and sometimes causes even more catastrophic and widely publicized consequences, such as serial killings and mass murders. Some evidence suggests that treatment can reduce the risk of SSD-related violence.³¹ Patients, their families, and the community would benefit from the identification of effective treatments to reduce persistent or recurrent hostility and the risk of overt aggression.

But what treatment? Evidence suggests that aggressive persons with schizophrenia, once identified, tend to be treated with long-term high-dose neuroleptics, “despite a lack of clear evidence that such treatment is effective” (³² p 640).

Four reviews of the available scientific literature have addressed this question. Brieden et al.³³ conducted a review of articles discussing the pharmacological treatment of aggression among persons with SSDs published

between 1980 and 2000. Based on a MEDLINE search, they identified “about ten articles” that directly addressed this issue. They consequently expanded their search to address treatment of aggression in all psychiatric disorders, and to include open label studies, cases series, and case reports. They included reports regarding emergency management, chronic treatment, inpatients, and outpatients, employing a variety of measures of hostility or aggression. While the authors acknowledge the importance of this early effort, the published data leaves important questions unresolved. They commented that there is “wide agreement” that clozapine is efficacious for the management of aggression and hostility in persons with schizophrenia, but did not cite a randomized controlled trial (RCT) supporting that statement. They cited two RCTs^{34,35} that reported that risperidone was more efficacious than other antipsychotics. The first study failed to report the proportion of subjects who completed or the relative efficacy of different doses. Fewer than one-half of subjects completed the second study. The authors cited one RCT reporting that adjunctive carbamazepine was effective in persistently aggressive patients with schizophrenia,³⁶ but that study disappointingly did not report the impact of treatment on hostility or aggression. They also cited one RCT reporting the efficacy of citalopram.³⁷ They did not state whether the results of the cited studies might have been confounded by concomitant administration of other psychotropics, classify the quality of the cited studies, or examine the level of evidence supporting a recommendation. These authors concluded that atypical antipsychotics “with a preference for clozapine” should be used to manage repetitive aggression in patients with schizophrenia, but qualified their review: “There is an urgent need to refine the treatment of aggression on the basis of specific studies to be done in the future.”

A similar review was authored by Fazel and Topiwala.³⁸ These authors state that they searched MEDLINE, EMBASE, and PsycInfo from 2000 to March of 2010, using the search terms *schizophren**, *psychos** AND *violen**, *aggress** AND *antipsychotic**, *neuroleptic**, *mood stabilizer**, *medication**, “as well as specific drug names.” They did not provide the drug names or limit the review to articles reporting management of persons diagnosed with schizophrenia spectrum disorders. They state, “Publications were *largely* selected from the past 5 years,” [emphasis added] although it is not clear on what basis older publications were excluded. They also searched the reference lists of the articles found in their

automated search. These authors identified a total of 18 relevant studies. They concluded 1) "There is randomized controlled trial evidence in support of a specific anti-aggressive effect of clozapine," 2) "Insufficient high-quality evidence has been published to recommend the use of atypical rather than typical antipsychotics in the management of violence in schizophrenia," 3) "The evidence to support the efficacy of adjunctive mood stabilizers is inconsistent," 4) "There is little evidence for the effectiveness of β -blockers in the management of aggressive patients, and these may be poorly tolerated," and 5) Tricyclic antidepressants (desimpramine and imipramine) and anticraving agents (naltrexone) "may be of benefit in dual diagnosis patients." These authors did not review trials of desimpramine, imipramine, or naltrexone for the management of aggression in persons with schizophrenia. Although the empirical basis for some of their conclusions and recommendations is underspecified, several of Fazel and Topiwala's conclusions bear consideration: 1) that the currently available literature is both limited and scientifically weak, 2) that the phenomenology under scrutiny is heterogeneous, and 3) that "As pathways to violence become better elucidated, we anticipate that pharmacological therapy will target specific symptom profiles..."

A third review authored by Buckley *et al.*³⁹ does not report a search method. The majority of papers discussed in this review were reports of medication trials to manage emergency room agitation in populations whose diagnoses varied from unknown to 100% schizophrenia. This review identified one single report of a medication trial for the management of persistent aggression.⁴⁰ Rather than offering practice recommendations based on their review, these authors deferred to the expert consensus guidelines of Allen *et al.*⁴¹ with respect to management of emergency agitation, and to the Schizophrenia Patient Outcomes Research Team (PORT) psychopharmacological treatment recommendations⁴² with regard to management of persistent aggression.

The previously cited PORT study represents the fourth available review of this topic. The authors conducted a MEDLINE search from January 2002 through March of 2008, using the search terms "schizophrenia" and the names of individual drugs, limiting the search to clinical trials published in English. The authors identified five reports of the efficacy of clozapine for the management of aggression in schizophrenia^{40,43–46} and six reports regarding the efficacy of other agents for this purpose.^{47–52} Based on this review the PORT authors recommended,

"A trial of clozapine should be offered to people with schizophrenia who present with persistent symptoms of hostility and/or display persistent violent behaviors" (⁴² p. 80).

We undertook a more comprehensive systematic review of the English language literature, attempting to identify every peer-reviewed study reporting a test of the hypothesis that a medication reduced either hostility or overt interpersonal aggression among persons with SSDs. We classified every such report, and considered whether the level of evidence, in toto, supports a recommendation or a guideline for clinical management of this important behavioral complication of SSDs.

METHODS

We employed four search strategies in an attempt to identify potentially relevant publications.

Search 1 was conducted in Ovid/Medline on August 10, 2009 using the following algorithm: [exp Schizophrenia/ OR schizophrenia.mp.] AND [[aggression.mp. OR exp Aggression/] OR [exp Violence/ OR violence.mp.] OR violent OR [hostility.mp. OR exp Hostility/]] AND [[exp Drug Therapy/ OR drug therapy.mp.] OR pharmacotherapy.mp. OR [clinical trial.mp. OR exp Clinical Trial/]]. This strategy yielded 314 citations.

Search 2 was conducted in PsycINFO August 10, 2009 using an algorithm devised by a Ph.D. in Library Science (Figure 1). This strategy yielded 115 citations.

Search 3 was conducted in Ovid/Medline on April 10, 2010 employing the Cochrane "Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008 revision); Ovid format" (⁵³ p. 138) (see Figure 2). This strategy identified 417 citations.

Search 4 was conducted in EMBASE on September 15, 2010 employing the Cochrane method (⁵³ p. 121–122): Free text terms: random\$ (\$ means truncation symbol), factorial\$, crossover\$, Cross over\$, Cross-over\$, placebo\$, doubl\$adj blind\$, singl\$ adj blind\$. assign\$, allocat\$, volunteer\$. Index terms (aka EMTREE terms): crossover-procedure, double-blind procedure, randomized controlled trial, single-blind procedure, and Other terms: schizophrenia, aggression, hostility. This strategy identified 324 citations.

Searches 1–4 were de-duplicated, yielding 804 unique citations. Searches 1–3 were repeated October 4, 2010. Four new abstracts were identified. All abstracts were reviewed; 264 of the 804 abstracts suggested that the

FIGURE 1. Search Algorithm Employed in Search 2

Schizophrenia/explode ("schizophrenia" or "acute schizophrenia" or "catatonic schizophrenia" or "childhood schizophrenia" or "paranoid schizophrenia" or "process schizophrenia" or "schizophrenia disorganized type" or "schizophreniform disorder" or "undifferentiated schizophrenia") AND [Aggressive behavior/explode ("aggressive behavior" or "aggressive driving behavior" or "animal aggressive behavior" or "animal predatory behavior" or "attack behavior" or "muricide" or "threat postures" or "coercion" or "conflict" or "arguments" or "family conflict" or "marital conflict" or "riots" or "violence" or "domestic violence" or "intimate partner violence" or "patient violence" or "school violence" or "violent crime" or "homicide" or "filicide" or "genocide" or "holocaust" or "serial homicide" or "physical abuse" or "political assassination" or "rape" or "acquaintance rape" or "terrorism" or "bioterrorism" or "workplace violence" or "war" or "nuclear war" or "aggressiveness") OR violence/explode ("violence" or "domestic violence" or "intimate partner violence" or "patient violence" or "school violence" or "violent crime" or "homicide" or "filicide" or "genocide" or "holocaust" or "serial homicide" or "physical abuse" or "political assassination" or "rape" or "acquaintance rape" or "terrorism" or "bioterrorism" or "workplace violence") AND [Clinical trials OR Drug Therapy/explode ("drug therapy" or "chemotherapy" or "hormone therapy" or "narcoanalysis" or "sleep treatment" or "polypharmacy" or "vitamin therapy")].

FIGURE 2. Search Algorithm Employed in Search 2

1. randomized controlled trial.pt
2. controlled clinical trial.pt
3. randomized.ab
4. placebo.ab
5. drug therapy.fs
6. randomly.ab
7. trial.ab
8. groups.ab
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. animals.sh. not (humans.sh and animals.sh.)
11. 9 not 10
12. Schizophrenia MESH
13. aggression MESH or aggression keyword
14. hostility MESH or hostility keyword
15. 13 or 14
16. 11 and 12 and 15.

corresponding full text articles possibly reported data regarding the efficacy of neuropharmacological agents for the management of either hostility, aggression, or violence in persons with SSDs. These 264 full text articles were obtained and reviewed. An additional 76 abstracts were obtained for all references in these 264 papers that appeared to represent empirical reports not otherwise captured by our search. Based on a review of those 76 abstracts, an additional 18 full text papers were obtained. One author (J.V.) reviewed the resulting total of 282 full text papers, identifying 179 articles that contained either data or statements regarding the efficacy of pharmacological agents for the management of hostility,

aggression, or violence. Searches 1–3 were repeated June 16, 2012. After de-duplication, review of abstracts, review of full texts, and review of papers identified in the reference sections of the newly found papers, seven additional publications were identified that reported relevant data.

The preliminary review of these 186 full text articles revealed the considerable, and problematic, diversity of research designs. In addition to the typical variation in medication trial design such as subject number, age, gender, severity of illness, medical exclusion factors, agent, dose, duration, blindness, allocation method, assessment measures, statistical method, proportion of completers, and intent to treat analysis, there were also differences in 1) diagnosis—e.g., studies confined to schizophrenia versus those that included mixed populations with schizophrenia spectrum disorders versus those that included "psychotic disorders" as well as mood disorders, 2) dependent variable—e.g., studies that regarded efficacy for the management of hostility or aggression as a primary outcome measure versus those (the overwhelming majority) that reported subscale measures of hostility as a secondary, often incidental, result, 3) clinical site—e.g., studies with inpatients (which often employed various selection criteria either for a history of responsiveness to antipsychotics or for treatment resistance) versus studies with outpatients, 4) adjunctive treatment—e.g., studies that investigated single medications (usually antipsychotics) for dual effects on thought disorder and behavior versus studies of adjunctive medications for behavior management, 5) aggressivity—e.g., studies that preselected aggressive subjects versus those (the majority) that did not. A few studies also conducted multivariate analyses to control for akathisia. Almost all of the controlled or comparison studies permitted concomitant administration of other psychotropic agents, yet no studies controlled for this potentially confounding factor.

It is unclear how meaningful it would be to collapse the results from such different study designs in an effort to identify conclusions that would be generalizable to the broad spectrum of persons with schizophrenia and their many variations of clinical circumstances. Given this diversity of research designs, therefore, we organized the review to address four questions:

1. Does evidence exist that any medication will reduce *overt aggression* in representative patients with SSDs that have not been preselected for exhibiting excessive aggression?

Corollary: Does evidence exist that one medication is more efficacious than another in reducing overt aggression in representative patients with schizophrenia spectrum disorders?

2. Does evidence exist that any medication will reduce *hostility* in representative patients with schizophrenia spectrum disorders?

Corollary: Does evidence exist that one medication is more efficacious than another in reducing *hostility* in representative patients with schizophrenia spectrum disorders?

3. Does evidence exist that any adjunctive medication will reduce *overt aggression* or *hostility* in persons with schizophrenia spectrum disorders?
4. Does evidence exist that any medication will reduce *overt aggression* or *hostility* in persons with schizophrenia spectrum disorders preselected for clinically problematic aggression?

The 186 full text articles were classified according to which of these questions their data addressed. In several studies^{52,54,55} agent 1 was compared with agent 2—which was regarded as an *active control* for the purposes of assuring assay sensitivity—as well as with placebo. In such studies, despite the generation of potentially relevant data, the investigator's stated intent was not to test the hypothesis that the active control agent 2 was efficacious of the treatment of schizophrenia, and the statistical analyses sometimes exclude results with respect to agent 2. For example:

The olanzapine group was included in the study in order to provide a concurrent active control group to confirm that the study as executed was adequate to detect a drug effect in the event of negative findings for paliperidone ER compared with placebo (i.e., assay sensitivity to detect a "failed trial"). The study was not designed to support statistical comparison of the paliperidone ER and olanzapine arms⁵² (p. 150).

This reporting strategy with respect to the active control arm is traditionally acceptable on the grounds that the efficacy of that control agent to treat schizophrenia has been reliably and repeatedly demonstrated.⁵⁶ However, because the active control agent has typically *not* been demonstrated to be efficacious for the management of hostility or aggression in SSDs, and because the statistical analysis of efficacy of the active control agent versus placebo is reported in several of these papers, we

judged that readers may profit by examining published data reporting changes in hostility/aggression measures associated with such active control treatments and we include the reported results in this review. A few studies (e.g.⁵⁷) classified their subjects as being "violent" versus "non-violent." The data were, therefore, judged relevant to more than one of our four questions, and their results are reported in more than one of our tables.

Using a standardized checklist, two investigators independently reviewed each article to extract data including the research design, clinical setting, number of subjects, proportion of completers, agents and doses compared, duration, outcome measure employed, concomitant psychotropics permitted, statistical method, and reported results. The investigators then compared the data they extracted and reconciled any differences—either in reportable data or in judgment regarding level of evidence—by consensus. The pair of investigators that reviewed each paper discussed and reached a consensus in regard to the applicable classification according to the American Academy of Neurology's recommendations for Levels of Evidence.^{58–60} Note: in these practice guidelines for classification of therapeutic articles, criterion "e" requires that studies of equivalence comparing two agents include a "standard treatment." Because no standard treatment has been established for aggression in schizophrenia, it is not possible for any RCT comparing of two drugs, lacking placebo control, to be Class I. Studies comparing the efficacy of two agents without a placebo control were, therefore, rated as Class II if they met all other Class I criteria, or as Class III or IV, depending on how many other criteria (e.g., percent completers) were fulfilled. Guidelines for the classification of clinical benefit propose that Class C (possibly effective) requires at least one Class II or two consistent Class III studies. When agents were proven effective by one Class II as well as by one consistent Class III study, we also classified the evidence of clinical efficacy as Class C. Class IV studies did not impact classification of efficacy but were included to make the universe of data available.

RESULTS

One hundred eighty-six peer-reviewed articles were identified that reported clinical effects of pharmacological agents on aggression or hostility in persons with SSDs, either as a primary outcome variable, a secondary

outcome variable, the focus of post hoc analysis, or an incidental finding derivable from tabulated results. Of these, a consensus was reached that 92 articles provided sufficient methodological information (e.g., number of subjects, diagnosis, interventions, outcome measures, percent completers, statistical analysis) to regard the data as reportable.

Multiple measures of aggression or hostility were employed in the reviewed reports. Studies that addressed overt aggression primarily employed the inpatient observational Overt Aggression Scale (OAS⁶¹), or the Modified Overt Aggression Scale (MOAS⁶²). Studies that addressed hostility primarily employed either individual items from the Positive and Negative Symptoms Scale (PANSS⁶³) or the Brief Psychiatric Rating Scale (BPRS⁶⁴), or factors comprised of clusters of related items from one of these two instruments. Note that the BPRS item content is wholly contained within the PANNS. Thus, commonly employed and somewhat related measures include

1. The BPRS hostility item,⁶⁴
2. The BPRS hostility factor, aka hostility/suspiciousness factor, aka Factor V, derived from the hostility, suspiciousness, uncooperativeness items,^{65,66}
3. The PANNS hostility item,⁶³
4. The PANSS uncontrolled excitement/hostility factor, derived from PANSS excitement and hostility items, aka "Marder factor 4,"³⁵
5. The PANSS hostility factor, aka "hostility cluster," derived from hostility, excitement, poor impulse control, and uncooperativeness items,⁶⁷⁻⁶⁹
6. The Aggression Risk Profile (derived from PANSS responses according to the violence potential assessment criteria in appendix 4 of the PANSS manual).⁶³

Other measures that are perhaps similar were reportedly employed, but neither described nor identified by citation, such as the PANSS "supplemental anger item,"⁷⁰ the PANSS "aggression supplemental scale,"⁷¹ and the "aggressiveness risk" score (perhaps referring to the Aggression Risk Profile).⁷²

The measures employed were sometimes reported ambiguously, in which case the scale that seemed to most likely have been used in a study was decided by consensus. Other identifiable measures employed included the Buss-Durkee Hostility Inventory,⁷³ the Plutchik Impulsivity scale,⁷⁴ the Nurses' Observation Scale for Inpatient Evaluation Irritability Scale,^{75,76} the Aggression and Social Dysfunction Scale,⁷⁷ the MacArthur Community Violence Interview,^{78,79} the Barratt Impulsiveness

Scale (BIS^{80,81}), the aggression severity measure of the Clinical Global Impression scale (CGI⁶⁵), the Personal and Social Functioning Scale, item 4: disturbing and aggressive behaviors,^{82,83} the Wittenborn Psychiatric Rating Scale Aggression item (WPRS⁸⁴), the anger item on the State-Trait Personality Inventory,⁸⁵ seclusion and restraint data, or *ad hoc* rudimentary measures such as occurrence or nonoccurrence of any known aggressive behavior during an arbitrarily selected time period (e.g.,^{57,86,87}) or a "rough evaluation" of aggressiveness.⁸⁸

For the purposes of this report, "hostility" refers to 1) The BPRS hostility item (no. 10), 2) the BPRS Marder hostility factor, 3) the BPRS Hostility/Suspiciousness factor score (mean of hostility, suspiciousness, and uncooperativeness items, 4) the PANSS hostility item, or 5) the PANSS uncontrolled hostility/excitement factor derived from the excitement, hostility, and impulse control items. The principal results are displayed in Tables 1–5 (to view the legend for these tables, see the data supplement accompanying the online version of this article) The narrative details the subset of studies pertinent to determining levels of evidence.

1. Does evidence exist that any medication will reduce overt aggression or physical violence in patients With schizophrenia spectrum disorders?^{79,89}

No Class I, II, or III RCTs were identified that tested this hypothesis. One large scale Class IV 2-year observational study (Swanson, et al., 2004a⁸⁹) compared the anti-aggressive impact of any conventional antipsychotic versus any atypical antipsychotic versus no treatment in 403 community dwelling persons with schizophrenia spectrum illness. Aggression was assessed by self-report, using the MacArthur Community Violence Interview,⁷⁹ as well as chart reviews and arrest records. In a time series analysis, atypical antipsychotics were significantly more likely to reduce violence than typical agents ($p < 0.05$). Adherence to atypical antipsychotics was also associated with reduced risk of violence. This effect appeared to be mediated by 1) decreased psychosis, 2) decreased substance abuse, and 3) decreased adverse medication effects. One conclusion was that medication noncompliance is an independent risk factor for community violence among persons with these disorders, even controlling for substance abuse.

We conclude that the data are insufficient to fulfill criteria for formal practice guidelines. Given current knowledge, the benefit of pharmacological intervention for the management of overt aggression in persons with

SSDs who have not been preselected for aggression is unproven (Level U).

Corollary: Does evidence exist that one medication is more efficacious than another in reducing overt aggression or physical violence in patients with schizophrenia spectrum disorders? 45, 46, 57, 87, 89–102 (Table 1)

Eighteen articles were identified that reported relevant data. No Class I studies were identified that tested this hypothesis. Two Class III studies reported evidence that clozapine was superior to haloperidol in reducing OAS measures in inpatients with SSDs.^{45,90} The first study permitted concomitant administration of benzodiazepines. The second permitted administration of lorazepam, diphenhydramine, and chloral hydrate. Neither study controlled for coadministration of these psychotropic medications. One Class III study reported that perphenazine was superior to quetiapine in reducing aggression assessed with the MacArthur Community Violence Interview.⁴⁶ One Class III study reported no difference in a comparison of chlorpromazine with thioridazine.⁹¹

We conclude that the clozapine is **possibly superior** to haloperidol for the management of overt aggression among inpatients with SSDs who have not been selected for aggression and who may be receiving other psychotropic medications (Level C). Given current knowledge, the comparative benefit of other pharmacological interventions is unproven (Level U).

2. Does evidence exist that any medication will reduce hostility in patients With schizophrenia spectrum disorders? 34,48,49,51,52,54,55,103–113 (Table 2)

Eighteen articles were identified that reported relevant data. No Class I studies were identified that tested this hypothesis. Four Class II studies^{52,104,105,107} and one Class III study⁵⁵ reported that paliperidone ER treatment was associated with greater reduction in measures of hostility than placebo among inpatients with SSDs. All five studies permitted concomitant administration of other psychotropics including benzodiazepines, antidepressants, barbiturates, pyrazolopyrimidine sedative/hypnotics, and anticholinergic agents. None controlled for this factor. Two Class II studies^{51,103} and one Class III study¹⁰⁸ reported tests of the efficacy of quetiapine versus placebo among inpatients. None of these controlled for concomitant psychotropics. One Class II study and the Class III study reported that quetiapine was associated with greater reduction in measures of hostility than placebo,

but the second Class II study reported no difference at the endpoint. A single Class II study reported that olanzapine treatment was associated with significantly greater reduction in hostility than placebo.¹⁰⁶ That study did not control for concomitant administration of other psychotropics. We conclude that the paliperidone ER treatment is **probably effective** for the reduction of hostility among inpatients with SSDs who have not been selected for aggression and who may be receiving other psychotropic medications (Level B). Quetiapine is **possibly effective** for this indication. Given current knowledge, the benefit of other pharmacological interventions for the management of hostility is unproven (Level U).

Corollary: Does evidence exist that one medication is more efficacious than another in reducing hostility in patients with schizophrenia spectrum disorders? 44,47, 50, 108, 114–131 (Table 3)

Twenty-five articles were identified that reported relevant data. One of these¹⁰¹ was also reported in Table 1 because overt violence was an outcome measure. Two papers^{34,109} were also reported in Table 2 because they include placebo arms. No Class I studies were identified that tested this hypothesis.

Two Class II and two Class III studies reported tests of the relative efficacy of clozapine versus other antipsychotics. One Class II inpatient study¹¹⁹ found that clozapine was significantly superior to chlorpromazine. The other Class II inpatient study¹¹⁵ did not find a statistically significant difference in efficacy. Both of the Class III studies comparing these agents reported that clozapine was superior to haloperidol—one among inpatients,⁴³ the other among outpatients.¹²¹ None of these studies controlled for the concomitant administration of other psychotropics. One Class II inpatient study³⁴ and one Class III outpatient study⁴⁷ reported evidence that risperidone was associated with significantly greater reduction in hostility versus haloperidol,³⁴ although another Class II¹¹⁴ study (including both in- and outpatients) reported no difference in efficacy for this indication. One Class II¹¹⁵ and one Class III study¹¹⁹ both reported that clozapine was more effective than chlorpromazine. Two Class III studies reported that clozapine was more effective than haloperidol.^{43,121} Single Class III studies reported the relative superiorities of haloperidol versus thiothixene,¹¹⁸ haloperidol versus risperidone,⁵⁰ clozapine versus risperidone,⁴³ risperidone versus perphenazine,¹²⁰ and amisulpride versus haloperidol.¹²³

TABLE 1. Evidence Pertaining to the Question Whether One Medication is More Efficacious Than Another in Reducing Overt Aggression or Physical Violence in Persons With Schizophrenia Spectrum Disorders

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Medication and Dose	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Level III studies											
Spivak et al., 2003 ⁹⁰	JCP	Open prosp	Inpatient	44	84.1%	Cloz 150–500 mg/day versus HAL decanoate 150–300 mg/month	6 months	1. OAS	Benzos	Cloz assoc. w sig. greater ↓ OAS	III
Stabenau, 1964 ⁹¹	PsychQuart	RCT	Inpatient	52	40/52=76.9%	Chlorp 100 - > 500 mg/day versus Thior 100 - > 500 mg/day	3 weeks	2. Plutchik IS	NR	2. Cloz assoc. w sig. greater ↓ IS No sig. Diff.	III
Swanson, 2008 ⁴⁶	BIP	RCT	Out	1445	653/1445=45.2%	Olan 7.5–30 mg/day versus Risp 1.5–6 mg/day versus Quet 200–800 mg/day versus Perph 8–32 mg/day versus Zip 40–160 mg/day	6 months	MacArthur	All except antipsychotics	Perph assoc. w sig. greater ↓ violence No other diff.	III
Volavka et al., 2004 ⁴⁵	J Clin PP	RCT	Inpatient	157	58%	Cloz 200–800 mg/day versus Olan 10–40 mg/day versus Risp 4–16 mg/day versus HAL10–30 mg/day	14 weeks	1. Incidents of overt agg. 2. OAS TAS	Lor; Diphenh; Chloral H	Cloz > others re. incidents; Cloz > HAL on OAS TAS	III
Level IV studies											
Bitter et al., 2005 ⁹²	Eur Psych	Post hoc analysis of Prosp. naturalistic study	Out-patient	5018 ^a	62.5%	Olan versus Cloz versus Risp versus HAL (doses NR).	6 months	Yes/no exhibiting “verbal or physical hostility/aggression”	NR	Proportion of patients exhibiting “verbal or physical hostility/aggression” ↓ with all rxes	IV
Buckley et al., 1995 ^{57b}	B Am Acad PL	Pros observ	Inpatient	30 [11 violent versus 19 non violent]		Before and after Cloz (dose NR)	12 months	S&R data compared in violent versus non-violent pls.	nr	Cloz = Larger decline in seclusion and restraint in “violent” subgroup	IV
Carney, 1984 ⁹³	Pharm ther	Pros observ	Inpatient, then Out-patient	23	20	Before and after clopenthixol decanoate ~200 mg/3 weeks	11 months	7 point agg. scale	Other antipsychotics; Benzos; procyclidine; benzhexol; TCAs	Sig. ↓ in agg. score	IV

TABLE 1. Evidence Pertaining to the Question Whether One Medication is More Efficacious Than Another in Reducing Overt Aggression or Physical Violence in Persons With Schizophrenia Spectrum Disorders (Continued)

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Medication and Dose	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Chiles <i>et al.</i> , 1994 ^{87c}	HCP	Retro	Inpatient	139	82.7% ^c	Before and after Cloz 200–900 mg/day	24 weeks	S&R data	NR	Cloz assoc. w ↓ use of S&R	IV
Dalal <i>et al.</i> , 1999 ^{94b}	CBMH	Pros observ	Inpatient	50 [20 violent]		Before and after Cloz, (n =465 mg/day)	12–27 months	Violent bhw [nurses' obser]	NR	At 12 m: 16/20 in violent subgroup "less severe violent bhw"	IV
Kuoppasalmi <i>et al.</i> , 1993 ⁹⁵	Psych Fenn	Retro	Inpatient	103	N/A	Before and after Cloz 150–900 mg/day	24 months	"Intensity" of agg bhw 0,1,2	Other antipsychotics; Benzos	Sig ↓ in intensity of agg. bhw.	IV
Mallaya <i>et al.</i> , 1992 ⁹⁶	JCP	Retro	Inpatient	107	N/A	Before and after Cloz (dose NR)	13 months	S&R data	NR	Cloz assoc. w ↓S&R	IV
Menditto <i>et al.</i> , 1996 ⁹⁷	Psych Serv	Prosp obs	Inpatient	22	100%	Cloz 400–700 mg/day + 'Social Learning' versus typical antipsychotics + 'Social Learning'	6 months	TSBC = # and freq of threats/ assaults	Lithium; AEDs	Cloz assoc. w ↓threats or assaults	IV
Spivak <i>et al.</i> , 1997 ⁹⁸	Clin NP	Prosp obs	Inpatient	14	100%	Before and after Cloz (n=223 mg/day)	18 weeks	11. OAS	NR	1. Cloz assoc. w ↓ agg.	IV
Spivak <i>et al.</i> , 1998 ⁹⁹	Clin NP	retro	Inpatient	60	N/A	Cloz (dose NR) versus typical antipsychotics (dose NR)	1 y	2. Plutchik IS 1. OAS	NR	2. Cloz assoc. w ↓impulsivity 1. Cloz assoc. w ↓agg. versus typicals	IV
Swanson <i>et al.</i> , 2004 ⁸⁹	Schiz Bull	Prosp obs	Out-patient	403	229/403=56.8%	Any atypical versus any typical (doses NR)	2 years	Composite index from: 1. Macarthur 2. Record review 3. Arrest record	NR	2. Cloz assoc. w ↓impulsivity versus typicals Compliance with atypicals assoc. w <violence versus typicals	IV
Swanson <i>et al.</i> , 2004 ¹⁰⁰	JCP	Prosp obs	Out-patient	403	NR ^d	Olan versus Risp (doses NR)	3 years	Composite index from: 1. Macarthur 2. Record review 3. Arrest record	NR	Olan compliance for one year or more assoc. w < violence versus risperidone	IV
Wilson, 1992 ^{101e}	HCP	Retro	Inpatient	37	N/A	Before and after Cloz 300–900 mg/day	12 months	# violent episodes; S&R data	Other antipsychotics	Cloz assoc. w ↓ viol episodes (no stats. reported)	IV

TABLE 1. Evidence Pertaining to the Question Whether One Medication is More Efficacious Than Another in Reducing Overt Aggression or Physical Violence in Persons With Schizophrenia Spectrum Disorders (Continued)

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Medication and Dose	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Wilson and Clausen, 1995 ⁶²	Psych Serv	Retro	Inpatient	100 ^f	N/A	Before and after Cloz 150–900 mg/day	25 months	# violent episodes	Other antipsychotics	Olan assoc. w ↓ viol episodes	IV

^aRe. Bitter et al., The investigation reportedly began with 7655 subjects, of whom 5018 received monotherapy, of whom 3135 completed. This report seems to be a post hoc analysis of a prospective study, but the method, as reported, is ambiguous.

^bBuckley, et al., 1995 and Dalal et al., 1999 are also reported in Table 3 because subsets of patients were preselected as violent.

^cAlthough Chiles et al., 1994 is a retrospective study, data were only reported for the subset that had completed 12 weeks of tx, so that the completion rate is only 82.7%.

^dRe. Swanson et al., 2004b: This paper included data on 124 completers but fails to report how many of the 403 patients were on one of the two study drugs at the start of the study period.

^eRe. Wilson, 1992: These results are reported in Table 1 because violence was monitored. They are also reported in Table 3 because in seven cases Cloz was employed as an adjunct to typical antipsychotic medications. The author does not stratify results for subjects with and without concomitant typical antipsychotics.

^fNote that 7/100 subjects in Wilson and Clausen, 1995 were not in the schizophrenia spectrum. These results represent comingling for different diagnoses.

We conclude that the clozapine treatment is **possibly more effective** than chlorpromazine, and risperidone is **possibly more effective** than haloperidol for the management of hostility among inpatients with SSDs who have not been selected for aggression and who may be receiving other psychotropic medications (Level C). The relative efficacy of clozapine versus haloperidol would qualify for Level B if one disregarded the difference between in- and outpatients, but that seems to violate the requirement for at least two *consistent* Class II studies.^{58–60} Given current knowledge, the comparative efficacy of other pharmacological interventions for the management of hostility among in- or outpatients is unproven (Level U).

3. Does evidence exist that any adjunctive medication will reduce overt aggression or hostility in persons with schizophrenia spectrum disorders?^{70–72,88,132–142}

(Table 4)

Fifteen articles were identified that reported relevant data. One paper¹³⁷ was also reported in Table 5 because the subjects were preselected for aggressiveness. Two Class I inpatient studies^{132,133} and one Class II inpatient study¹³⁶ reported evidence that adjunctive propranolol, 160–640 mg/day (the majority receiving >240 mg/day) combined with neuroleptic medications reduced anger,¹³² nurses' observations of irritability,¹³³ or overt violence.¹³⁶ A single Class III study¹³⁷ reported a benefit from adjunctive pindolol 15 mg/day. One Class II inpatient study¹³⁵ and one Class III inpatient study⁷⁰ reported reductions in measures of impulse control or anger with adjunctive valproate. The former added valproate to risperidone; the latter added valproate to either risperidone or olanzapine. However, a third study of adjunctive valproate reported no significant benefit.¹³⁸ These studies collectively permitted concomitant administration of benzodiazepines, propranolol, chloral hydrate, benztropine and zolpidem and did not control for this factor. One Class II study⁷² reported that perphenazine combined with famotidine was superior to perphenazine alone in reducing the PANSS aggressiveness risk score. One class II study¹³⁴ reported that antipsychotics plus s-adenyl methionine (SAM-e) was superior to antipsychotics alone in reducing OAS scores in a subset of patients carrying the low activity catechol-O-methyltransferase COMT codon 158 polymorphism—an effect the authors speculated might relate to SAM-e's reported enhancement of COMT activity.

We conclude that the adjunctive propranolol at doses of 160–640 mg/day is **possibly effective** in mitigating

TABLE 2. Evidence Pertaining to the Question Whether Any Medication Will Reduce Hostility in Persons With Schizophrenia Spectrum Disorders

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Level II studies											
Borison <i>et al.</i> , 1996 ⁶³	J Clin PP	RCT	Inpatient	109	46%	Quet 75–750 mg/day versus placebo	6 weeks	BPRS H/S Factor V	Chloral H; Benztr; Diphenh	No diff. at endpoint	II
Canuso <i>et al.</i> , 2009 ⁶⁴	AJP	RCT	Inpatient	399	70%	PAL ER 9–12 mg/day versus quetiapine 600–800 mg/day versus placebo	2 weeks	PANSS UH/E factor	Lorazepam; midazolam; amobarbital sodium; zaleplon; zolpidem; Benztr “or equivalent”	PAL assoc. w sig. greater ↓ in UE/H versus placebo	II
Canuso <i>et al.</i> , 2010 ⁶⁵	J Aff D	Pooled anal of Davidson 07, Kane 07, Marder 07	In- & out-patient	193 (subset w “prominent affective sx’s”)	46%	PAL ER 3–12 mg/day versus placebo	6 weeks	1. PANSS HI	Benzos; AntiD	1. PAL assoc. w sig. greater ↓ in HI versus placebo 2. No results reported re. PSP	II
Corrigan <i>et al.</i> , 2004 ⁶⁶	Bio Psych	RCT ^a	Inpatient	467	72.2%	Some 1.5 versus 10 versus 60 mg/day versus Olan 15 mg/day versus placebo	6 weeks	PANSS UH/E	Lor; Fluni; Chloral H; Benztr; benzhexol Hcl; Diphenh	1. Olan assoc. w sig. greater ↓ in UE/H versus placebo ⁵ 2. Some=no diff. versus placebo	II
Czobor <i>et al.</i> , 1995 ^{34b}	J Clin PP	RCT	Inpatient	139	NR	Risp 2–16 mg/day versus HAL 20 mg/day versus placebo	8 weeks	PANSS HI	Benzos; Chloral H; AntiCh	1. Risp assoc. w greater ↓ in HI than HAL 2. Risp assoc. w greater ↓ in H versus placebo (trend)	II
Kahn <i>et al.</i> , 2007 ⁵¹	JCP	RCT	Inpatient and outpatient	556	78%	Quet XR 400 mg/day versus Quet XR 600 mg/day versus Quet XR 800 mg/day versus Quet XR 400 mg/day versus Quet IR 400 mg/day versus placebo	6 weeks	PANSS HF	AntiCh; Lor; Oxa; “sedatives and hypnotics”	All doses and forms of Quet assoc. w sig. greater ↓ in HF versus placebo	II
Kane <i>et al.</i> , 2007 ⁵²	Schiz Res	RCT	Inpatient	628	66%	PAL ER 6 versus 9 versus 12 mg/day versus Olan 10 mg/day versus placebo	6 weeks	1. PANSS UH/E	Benzos; AntiD	1. PAL assoc. w sig. greater ↓ in UE/H versus placebo 2. No results reported re. PSP	II
Meltzer <i>et al.</i> , 2008 ⁶⁷	JCP	Pooled reanalysis ^a	Inpatient	1306	74%	PAL ER 3 versus 6 versus 9 versus 12 versus 15 mg/day versus Olan 10 mg/d ^N versus placebo	6 weeks	PANSS UH/E	Benzos; AntiD	1. PAL 6, 9, 12 Or 15 mg/day assoc. w sig. greater ↓ in UE/H versus placebo	II

TABLE 2. Evidence Pertaining to the Question Whether Any Medication Will Reduce Hostility in Persons With Schizophrenia Spectrum Disorders (Continued)

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Level III studies											
Chengappa et al., 2003 ¹⁰⁸	Clin Ther	RCT ^c	Inpatient	257	52.9%	Quet 150–750 mg/day versus HAL 12 mg/day versus placebo	6 weeks	BAS=agitation score derived from BPRS	Lor; Chloral H	1. Quet assoc. w greater ↓ in BAS versus placebo 2. HAL assoc. w greater ↓ in BAS versus placebo 3. No sig. diff. in size of ↓ in BAS between Quet +HAL 1. PAL 6 or 12 assoc. w sig. greater ↓ in UE/H than placebo 2. Olan assoc. w ↓ in UE/H 3. No results reported re PSP 4. (no stats reported)	III
Marder et al., 2007 ⁵⁵	Bio Psych	RCT	Inpatient	444	43%	PAL ER 6 versus 12 mg/day versus Olan 10 mg/day versus placebo	6 weeks	PAINSS UH/E	Benzos; AntiD; AntiCh; NSAIDs	1. PAL 6 or 12 assoc. w sig. greater ↓ in UE/H than placebo 2. Olan assoc. w ↓ in UE/H 3. No results reported re PSP 4. (no stats reported)	III ^d
Level IV studies											
Aleman and Kahn, 2001 ¹⁰⁹	Eur NP	Meta-anal	Inpatient	2248 ²	NR	Risp versus typical antipsychotics versus placebo	Varied	Varied	NR	1. Risp assoc. w greater ↓ H or agg. versus typical antipsychotics 2. Risp assoc. w greater ↓ H or agg. versus placebo	IV ^e
Buckley, 2004 ¹⁸	Cur Med Res Op	Meta-anal	Inpatient	624	NR	Quet 150–750 mg/day versus placebo	6 weeks	1. BPRS HI 2. BPRS HF	Chloral H; Lor; Other Benzos; Benztr; Diphenh	Quet assoc. w greater ↓ HI and HF versus placebo	IV ^f
Davidson et al., 2007 ⁵⁴	Schiz Res	RCT ^a	Inpatient	618	59%	PAL ER 3 versus 9 versus 15 mg/day versus Olan 10 mg/d ¹ versus placebo	6 weeks	PAINSS UH/E	Benzos; AntiD; AntiCh;	1. PAL assoc. w sig. greater ↓ in UE/H than placebo	IV ^g
Kane et al., 2011 ¹¹⁰	JCP	RCT	NR	386	54%	Asen (n=17.6 mg/d) versus placebo	26 weeks	PAINSS HF	Benzos; Partial benzo agonists; nonbenzo hypno tics; AntiD; mood stabilizers; "EPS medication"	1. Asen assoc. w sig. ↓ HE 2. Impact of asenepine versus placebo=NR	IV

TABLE 2. Evidence Pertaining to the Question Whether Any Medication Will Reduce Hostility in Persons With Schizophrenia Spectrum Disorders (Continued)

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Marder and Meibach, 1994 ¹¹¹	AJP	RCT	Inpatient	388	47%	Risp 2 versus 6 mg/10 versus 16 mg/day versus HAL 20 mg/day versus placebo	8 weeks	PANSS HI	Lor; Chloral H; AntiP	1. Risp versus placebo=NR 2. Risp 6 mg. Assoc. w sig. ↓ from baseline PANSS HI	IV
Simopoulos et al., 1974 ¹¹²	Arch Gen Psych	RCT	Inpatient	76	68.4%	DPH 375–625 mg/day versus placebo	8 weeks	BPRS HI	NR	1. DPH assoc. w less H at 4, not 8 weeks PANSS HI	IV ^h
Singer and Lam, 1973 ¹¹³	J Int Med Res	RCT	Inpatient	33	91%	Cloz 200–600 mg/day versus placebo	2 weeks	BPRS HI	NR	Cloz assoc. w greater ↓ in H than placebo (no stats reported)	IV
Volavka et al., 2005 ⁴⁵	JCP	Post hoc anal. of pooled data ⁱ	Inpatient	1476	NR	1. ARI versus placebo 2. ARI versus HAL versus placebo	4 weeks	PANSS HI	Lor; Benztr	1. Both ARI and HAL assoc. w sig. greater ↓ in HI than placebo; 2. No diff. between ARI and HAL	IV

^aIn Corrigan et al., 2004, Davidson, et al., 2007, and Meltzer et al., 2008, Olan was employed as an assay sensitivity medication. We note the reported significant effects on behavioral outcomes, although this was not the primary focus of the studies.

^bCzobor et al., 1995 is also reported in Table 2 because, in addition to the placebo control arm, it compares two active agents.

^cChengappa et al., 2003 is a post hoc reanalysis of an RCT.

^dMarder et al., 2007 demoted because, in addition to low completion rate, no statistics were reported.

^eAleman and Kahn, 2001 demoted because one of the seven studies in this meta-analysis (Blin et al., 1996) reported no results on the variable hostility or aggression. Buckley, 2004 is a combined analysis of three registration trials: Arvanitis et al., 1997; Borison et al., 1996; and Small et al., 1997. This report was demoted because neither Arvanitis nor Small reported any measures of aggression or hostility, and Buckley's method does not account for his provision of this data.

^fDavidson et al., 2007 was demoted because they *excluded* patients at risk for violence, making their sample nonrepresentative.

^hSimopoulos et al., 1974 was demoted because they dropped assaultive patients from study, making their sample nonrepresentative.

ⁱVolavka et al., 2005 is an analysis of data pooled from five studies: Petrie et al., 1997; Daniel et al., 2000; Kane et al., 2002; Potkin et al., 2003; and "data on file, Bristol-Myers Squibb." Not all studies reported concomitant medications.

TABLE 3. Evidence Pertaining to the Question Whether One Medication Is More Efficacious Than Another in Reducing Hostility in Persons With Schizophrenia Spectrum Disorders

Study and Evidence	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Psychotropics Permitted	Results	Class
Class II Studies^a											
Czobor et al., 1995 ^{34,b}	J Clin PP	RCT	Inpatient	139	NR	Risp 2–16 mg/day versus HAL 20 mg/day versus placebo	8 weeks	PANSS HI	Benzos; Chloral H; AntiCh	1. Risp assoc. w sig. greater ↓ in HI than HAL 2. Risp assoc. w greater ↓ in H versus placebo (trend) No diff. in impact on HF	II
Min et al., 1993 ¹¹⁴	Yon MJ	RCT	In- and outpatient	35	91.4%	Risp 5–10 mg/day versus HAL 5–10 mg/d	8 weeks	BPRS HF	Lor; oxazepam; Benztr		II
Niskanen et al., 1974 ¹¹⁵	Psych Fenn	RCT	Inpatient	48	100%	Cloz 75–1000 mg/day versus Chlorp 75–800 mg/d	40 days	BPRS HF	NR	Cloz assoc. w sig. greater ↓ HF versus Chlorp (NS)	II
Seth et al., 1979 ¹¹⁶	Cur Ther Res	RCT	Inpatient	72	88.9%	Lox 20–90 mg/day versus Trif 5–45 mg/day	12 weeks	BPRS HI	NR	Trif assoc. w sig greater ↓ HI versus Lox. Both agents assoc. w sig. greater ↓ HI versus baseline	II
Vyas and Kalla, 1980 ¹¹⁷	Cur Ther Res	RCT	Inpatient	30	100%	Lox 30–90 mg/day versus Chlorp 300–900 mg/day	6 months	BPRS HI	NR	Lox assoc. w sig. greater ↓ HI versus Chlorp	II
Class III studies											
Abuzzahab and Zimmerman, 1982 ¹¹⁸	JCP	CT [not random]	Out-patient	46	56.5%	HAL 5–40 mg/day versus Thioth 10–80 mg/day	24 weeks	BPRS H/S	AntiP; "concomitant medications for patients' well-being"	HAL assoc. with sig. greater ↓ H/S versus Thioth	III
Citrome et al., 2001 ⁴³	Psych Serv	RCT	Inpatient	167	58%	Cloz 200–800 mg/day versus Olan 10–40 mg/day versus risperidone 4–16 mg/day versus HAL 10–30 mg/d	14 weeks	PANSS HI	Benztr; PROP; Lor; Diphenh; Chloral H	Cloz assoc. w sig. greater ↓ HI versus Risp and HAL but not versus Olan	III
Claghorn et al., 1987 ¹¹⁹	J Clin PP	RCT	Inpatient	151	58% ^c	Cloz 150–900 mg/day versus Chlorpr 300–1800 mg/day	≥ 25 days	BPRS H/S	NR	Cloz assoc. w sig. greater ↓ H/S versus Chlorp	III
Gaebel et al., 2007 ⁵⁰	JCP	RCT	In- and outpatient	158	30.4% ^d	HAL 1–8 mg/day versus Risp 1–8 mg/day	8 weeks inpt. + 10 months outpt	PANSS UH/E	All except other antipsychotics or mood stab.	No sig. diff.	III

TABLE 3. Evidence Pertaining to the Question Whether One Medication Is More Efficacious Than Another in Reducing Hostility in Persons With Schizophrenia Spectrum Disorders (Continued)

Study and Evidence	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Psychotropics Permitted	Results	Class
Høyberg et al., 1993 ¹²⁰	Acta Psych Scand	RCT	Inpatient	107	73%	Risp 5–15 mg/day versus Perph 16–48 mg/day	8 weeks	BPRS HF	Benzos; Orphenadrine ^e	Risp assoc. w sig. greater ↓HF versus Perph	III
Kane et al., 2001 ¹²¹	Arch Gen Psych	RCT	Out-patient	71	51%	Cloz 200–800 mg/day versus HAL 4–16 mg/day	29 weeks	BPRS H/S	Lor; Benztr	Cloz assoc. w sig. greater ↓H/S versus HAL	III
Marder et al., 2003 ⁴⁷	AJP	RCT	Outpatient	63	46%	HAL M=4.5 mg/day at 2y versus Risp M=5.7 mg/day at 2y (each arm w versus w/o 'enhanced skills training')	2 years	1. BPRS HF 2. SCL-90-R AH ^f	AntiCh; PROP; others NR	Risp assoc. w greater ↓AH versus HAL; No sig. diff. on HF	III
McEvoy et al., 1991 ¹²²	Arch Gen Psych	RCT	Inpatient	47	68%	HAL (m=3.4 mg/d) versus HAL (m=11.6 mg/day)	2 weeks	BPRS H/S	Lor; Biperiden; Diphenh	Higher dose HAL assoc. w sig. greater ↓H/S versus lower dose HAL. However, no sig. diff. on HI.	III
Muller et al., 2002 ¹²³	J Clin PP	RCT	Inpatient	319	74%	AMIS 100 versus 400 versus 800 versus 1200 mg/day versus HAL 16 mg/day	4 weeks	BPRS H/S	Benzos; Chloral H	1. AMIS 400 and 800 assoc. w greater ↓H/S versus AMIS 100 or HAL	III
Peuskens et al., 1995 ¹²⁴	BJP	RCT	Inpatient	1362	75%	Risp 1 versus 4 versus 8 versus 12 versus 16 mg/day versus HAL 10 mg/day	8 weeks	BPRS "hostility cluster"	Lor; Oxa; Tem; biperiden; procyclidine	Risp 4, 8, 12, or 16 mg/day or HAL 10 mg/day assoc. w greater ↓H versus Risp 1 mg/d	III
Wang, 2006 ¹²⁵	J Psych Res	RCT	Out-patient	36	63.9%	Risp 2–6 mg/day versus Olan 5–15 mg/day	12 weeks	PANSS UH/E	NR	Risp assoc. w sig ↓UE/H versus baseline, but not versus Olan	III
Class IV studies											
Aleman and Kahn, 2001 ^{109g}	Eur NP	Meta anal	Inpatient	2248	NR	Risp versus typical antipsychotics or placebo	Varied	Varied	NR	1. Risp assoc. w greater ↓H or agg. versus typical antipsychotics 2. Risp assoc. w greater ↓H or agg. versus placebo	IV
Arango, 2003 ¹²⁶	AJP	RCT	Out-patient	75	85.3%	Cloz 200–600 mg/day versus	10 weeks	BPRS HI	Benztr	1. Cloz assoc. w no sig. ↓HI 2. HAL assoc. w ↓ HI	IV

TABLE 3. Evidence Pertaining to the Question Whether One Medication Is More Efficacious Than Another in Reducing Hostility in Persons With Schizophrenia Spectrum Disorders (Continued)

Study and Evidence	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Psychotropics Permitted	Results	Class
Conley et al., 2003 ⁴⁴	J Clin PP	RCT (cross over)	Inpatient	13	73.9%	HAL 10–30 mg/day Olan 50 mg/day versus Cloz 300–450 mg/day	16 weeks	PANSS HF	Lor; Benztr	No sig. diff.	IV ^h
Ebrahim et al., 1994 ¹²⁷ⁱ	HCP	Retro observ.	Inpatient	53	51%	Before and after switch to Cloz 87.5–850 mg/day	6 months	1. BPRS HI 2. S&R data	Typical antipsychotics; enalapril; nifedipine	1. Cloz assoc. w sig. ↓HI and ↓S&R	IV
Herman, 1997 ¹²⁸	Aust NZ J MHN	Prosp observ	Inpatient	11	NR	Before and after switch to Cloz 375–600 mg/day	5–16 months	BPRS HI	NR	Cloz assoc. w sig. ↓HI	IV
Levinson et al., 1992 ¹²⁹	BJP	RCT	Inpatient	61	67%	Fluph 10 to 30 mg/day (M=21 mg/day)	29 days ^j	BPRS HI	Chloral H; sodium amytal; Benztr	Fluph Assoc. w ↓HI	IV
Mann et al., 1984 ¹³⁰	Pharm psych	Open	Inpatient	14/	78.6%	Before and after AMIS mean 675 mg/day	28 days	BPRS HI	Amityryptiline; lorazepam; biperiden	AMIS assoc. w sig. ↓ HI	IV
Volavka et al., 1993 ¹³¹	J Clin PP	Prosp observ	Inpatient	223	82%	Before and after switch to Cloz (dose NR)	1 years	BPRS HI ^k	NR	Cloz assoc. w ↓HI	IV
Wilson, 1992 ¹⁰¹	HCP	Retro	Inpatient	37	N/A	Before and after Cloz 300–900 mg/day ^l	1 years	1. # violent episodes 2. # S&R episodes	Phenytoin; divalproex	↓violent episodes and S&R episodes after switch to Cloz (sig. N/R)	IV

^aNo studies in this category can be class I because there is no standard treatment against which to compare any rx (fails “e” criterion).

^bCzobor et al., 1995 is also reported in Table 2 because there was a placebo control arm.

^cClaghorn et al. 1987 reported data to 8 weeks on a subgroup of 36 patients. The results reported here are for the subset of patients regarded by the authors as having reached the “endpoint” = “whenever patients completed double blind treatment.”

^dRe. Gaebel et al., 2007: The authors performed an intent to treat analysis on 151/158 subjects (95.6%) and a completer analysis on 48/151 (30.4%). The results were the same. Subjects at five of thirteen centers were also randomized to one of two psychotherapeutic interventions. The paper was demoted both because of the low proportion of completers and the failure to stratify results by nonpharmacological intervention.

^eHoyberg et al. 1993 do not report all the concomitant medications they permitted.

^fRe. Marder et al., 2003: 1. Baseline Anger-hostility measures obtained when all subjects on HAL 8 mg/d; 2. Authors failed to report whether enhanced skills training impacted the efficacy of medications on AH.

^gAleman and Kahn, 2001 is also reported in Table 2 because it includes a placebo arm. The total number of subjects in this paper was derived from the source papers. Since not all of those papers reported % completion, this cannot be reported for this meta-analysis. This paper was demoted from Class III because one of the seven studies in this meta-analysis (Blin et al., 1996) reported no results on the critical variable of hostility or aggression.

^hConley et al., 2003, was demoted since, as a letter, it cannot be regarded as peer-reviewed.

ⁱEbrahim et al., 1994 was conducted at a forensic hospital. While it probably included many aggressive patients, the study is not listed in Table 3 because the authors fail to report the proportion of aggressive patients.

^jLevinson et al., 1992 was a 29 day study. Efficacy was only significant to the 22nd day, not to endpoint.

^kThe raters in Volavka et al., 1993 had minimal training with the assessment instruments and some violated the rating rules.

^lWilson, 1992 is also reported in Table 1 because overt violence was monitored. Results are also reported here because, in seven cases, Cloz was employed as an adjunct to typical antipsychotics. (30/37 subjects discontinued typical antipsychotics at some point during the trial.)

irritability and/or anger in inpatients who have not been selected for aggression (Level B). Our caution (demoting the level of confidence from *probable* to *possible* despite two Class I and one Class II supportive studies) stems from the fact that the relevant studies were not consistent in either the concomitant antipsychotic agent or the measures of outcome, which technically requires demoting confidence in the evidence by at least one Class. A single positive replication study would shift the level of confidence to “probable.” We also conclude that adjunctive valproate combined with risperidone is **possibly effective**, acknowledging that one of the two supportive studies monitored impulsivity and the other monitored anger (Level C). Adjunctive famotidine plus perphenazine is **possibly effective** for reducing impulsivity among such patients (Level C). Adjunctive SAM-e, combined with antipsychotics, is **possibly effective** for reducing aggression risk among the subset of such patients with the low activity COMT polymorphism (Level C). Given current knowledge, the efficacy of other adjunctive medications interventions is unproven (Level U).

4. Does evidence exist that any medication will reduce overt aggression or hostility in persons with schizophrenia spectrum disorders preselected for clinically problematic aggression?^{36,40,57,86,93,143–159} (Table 5)

Twenty-three articles were identified that reported relevant data. Two of these^{57,93} were also reported in Table 1 because the studies included some nonviolent patients. (That is, Buckley *et al.*, 1995⁵⁷ investigated the impact of clozapine on seclusion and restraint occurrence among 19 “non-violent” and 11 “violent” patients. Table 5 reports the findings with regard to the “violent” subgroup. Carney, 1984⁹³ investigated the impact of clopenthixol decanoate on 23 patients who exhibited a range of aggressive behavior with a mean of 1.71 on a four point scale. It was not possible to disaggregate the reduction in aggression observed among the more versus less aggressive subjects.) One study¹³⁷ was also reported in Table 2 because this was an adjunctive therapy trial. No Class I or II studies were identified that tested this hypothesis. Two Class III reports^{40,147} of what appears to have been a single RCT found evidence that, among physically assaultive inpatients, clozapine treatment was associated with greater reductions in MOAS scores compared with olanzapine or haloperidol. This study did not control for coadministration of multiple other psychotropic agents. Single Class III studies reported benefits of depot zuclopenthixol,¹⁴³ loxapine,¹⁴⁶ and adjunctive pindolol.¹³⁷

We tentatively conclude that the clozapine is **possibly more effective** than olanzapine or haloperidol for reducing aggression among physically assaultive inpatients (Level C). Our caution is related to the fact that it is not clear whether the two supportive publications^{40,147} are reporting a single study. Given current knowledge, the efficacy of other medications for the management of hostility or aggression among persons with SSDs preselected for clinically problematic aggression is unproven (Level U).

DISCUSSION

The available evidence supports several conclusions relevant to clinical practice:

1. Paliperidone ER is probably effective for the management of hostility among inpatients with SSDs who have not been preselected for aggression (Level B).
2. Clozapine is possibly more effective than haloperidol for the management of overt aggression and possibly more effective than chlorpromazine for the management of hostility among inpatients with SSDs who have not been selected for aggression (Level C).
3. Clozapine is possibly more effective than olanzapine or haloperidol for reducing aggression among physically assaultive inpatients with SSDs (Level C).
4. Adjunctive propranolol, valproic acid, and famotidine are possibly effective for reducing aspects of hostility or aggression among inpatients with SSDs (Level C).

To the best of our knowledge, this systematic review provides the first comprehensive investigation determining what is known about the efficacy of medications to manage aggression and/or violence among persons with SSDs. Even though most of the available peer-reviewed studies addressed hostility rather than overt aggression, evidence exists that verbal aggression or hostility correlate with physical aggression.¹⁶⁰ Moreover, in a study exploring the relationship between emotional status, cognitive capacity, and aggressive behavior among persons with SSDs, the best model for aggression behavior was a path from “anger emotion to aggressive behavior.”¹⁶¹ Therefore, agents that were found to be probably or possibly effective for the management of hostility among persons with SSDs may also prove possibly effective for reducing the more serious social and public health problem of violence. We believe that the present findings offer the strongest available evidence-based guidance regarding

TABLE 4. Evidence Pertaining to the Question Whether Any Adjunctive Medication Will Reduce Overt Aggression or Hostility in Persons With Schizophrenia Spectrum Disorders

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Class I studies											
Maoz et al., 2000 ¹³²	Eur Psychol	RCT	Inpatient	42	81%	HAL 20–30 mg/d +PROP (m=159 mg/d) versus HAL +placebo	8 weeks	1. OAS 2. Agg Behav Seq Para 3. State-Trait PI anger 4. MAI 5. CGI-A	Benzos, biperiden	1. Comb. rx assoc. w sig. lon State-trait PI anger 2. No diff on OAS, CGI-A, or MAI at 8w	I
Pugh et al., 1983 ¹³³	BJP	RCT	Inpatient	41	93%	Neuroleptic+PROP 160–640 mg/day versus neuroleptic +placebo	12 weeks	NOSIE IS	NR	Combo rx assoc. w sig. greater ↓NOSIE IS versus placebo	I
Strous et al., 2009 ¹³⁴	Eur NP	RCT	NR	18 with low activity COMT polymorph	89%	Adjunct SAM-F 800 mg/d +antipsychotics versus placebo +antipsychotics	8 weeks	1. OAS 2. Life Hx Agg	All except antipsychotics	Adj SAM-F assoc. w sig. lon OAS in this genetic subset	I
Class II studies											
Farzin et al., 2005 ⁷²	Iran JMS	RCT	Inpatient	30	NR	Perph 40 mg/d+Fam 60 mg/day versus perph+placebo	6 weeks	PANSS "Aggressiveness risk score"	Biperiden	Combo rx assoc. w ↓agg. risk scores	II
Omrani et al., 2007 ¹³⁵	IJPBS	RCT	Inpatient	32	NR	Risp 6 mg/d+VPA max 20 mg/kg/day "if tolerated" versus Risp +placebo	4 weeks	PANSS Impulse control item	Lor	Combo rx assoc. with ↓PANSS impulse control score	II
Yorkston et al., 1977 ¹³⁶	Lancet	RCT	Inpatient	14	NR	Typical antipsychotic +PROP "< 500 mg/d" versus typical antipsychotic +placebo	12 weeks	Nurses' rating of violence	NR	Adj PROP assoc. w sig. ↓ violence	II
Class III studies											
Casey et al., 2003 ⁷⁰	NeuroPP	RCT	Inpatient	249	67%	Olan 15 mg/day versus Risp 6 mg/day versus Olan+VPA	28 days	PANSS "Suppl Anger Item" ^a	Chloral H; zolpidem; Lor; PROP; Benztr	Antipsych+VPA assoc. w sig. greater lin PANSS "suppl Anger Item" versus antipsych alone	III
Caspi et al., 2001 ^{137b}	Int Clin PP	RCT/crossover	Inpatient	30 "at least 4 major agg. episodes within 2 months"	76.6%	Antipsychotic agent +PIN 15 mg/day versus antipsychotic agent+placebo	20 weeks	OAS	Diaz, CBZ; biperiden	Adj PIN assoc. w sig. ↓; 1. # and severity of agg. Incidents twd. other persons 2. # agg. and severity of agg. incid. twd. objects.	III

TABLE 4. Evidence Pertaining to the Question Whether Any Adjunctive Medication Will Reduce Overt Aggression or Hostility in Persons With Schizophrenia Spectrum Disorders (Continued)

Study and Evidence Level	Journal	Study Type	Setting	N	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Citrome et al., ³⁸ 2004	Psych Serv	RCT	Inpatient	249	67%	Olan 15 mg/day versus Risp 6 mg/day versus olanzapine 500–3500 mg/day versus Risp+VPA	28 days	PANSS HI	Chloral H ₂ zolpidem; Lor; PROPR; Benztr	No diff. at endpoint	III
Class IV studies											
Behdani, et al., ⁷¹ 2008	Eur NPP	RCT	Inpatient	64 female	NR	Risp 6 mg/d +estradiol 0.05 mg/day versus Risp+placebo	8 weeks	PANSS "Aggression supplemental scale" ^c	NR	Estradiol assoc. w sig. ↓PANSS "Aggression supplemental scale"	IV
Gerlach et al., ⁸⁸ 1975	Pharmako	RCT	Inpatient	11 w TD ^d	NR	Lithium sulfate (0.8–1.2 meq/l) versus placebo	42 days	"Rough evaluation" of agg.	NR	9/11 exhibited ↓ agg.	IV
Littrell, et al., ³⁹ 2004	JCP	prospeOpen	Out-patient	10	NR	Before and after Olan (dose NR) + VPA (plasma 50–100 µg/mL)	12 months	PANSS HI	None	Sig. ↓H	IV
Suzana et al., ⁴⁰ 2009	Eur NPP	RCT	NR	NR	NR	HAL versus Risp versus Cloz versus HAL+VPA or CBZ versus Risp+VPA or CBZ (doses NR)	4 weeks	PANSS HI	NR	1. Cloz alone assoc. with sig greater ↓in H than Risp or HAL 2. Cloz+either adjunct assoc. with sig. greater ↓in H No diff in H	IV
Wassef et al., ⁴¹ 2001	J Clin PP	Prospec observ	Inpatient	30	100%	HAL 20 mg/day w or w/o adjunctive VPA titrated to 80–100 µg/mL.	22 days	BPRS HI	NR		IV
Yoshimura et al., ⁴² 2007	Pharmpsych	Pros observ	Inpatient	12	100%	Before and after adjunctive VPA 400–800 mg/day added to Risp 2–6 mg/day	4 weeks	PANSS HI	NR	Adj VPA assoc. w sig. ↓ H	IV

^aRe. Casey et al., 2003: It is not clear what the "supplemental anger item" refers to.

^bCaspi et al., 2001 is also reported in Table 5 since these are aggressive patients.

^cRe. Behdani, et al., 2008: It is not clear from the text how the "Aggression supplemental scale" was derived in this study

^dRe. Gerlach et al., 1975: Study began with 20 patients of various diagnoses, all with neuroleptic induced "bucco-lingual-masticoric" tardive dyskinesia. Five dropped out. Eleven of the remaining 15 had schizophrenia.

TABLE 5. Evidence Pertaining to the Question Whether Any Medication Will Reduce Overt Aggression or Hostility in Persons With Schizophrenia Spectrum Disorders Prescribed for Clinically Problematic Aggression

Study and Evidence Level	Journal	Study Type	Setting	N/Selection Factor	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Class III studies											
Arango, et al., 2006 ⁴³	Eur Psych	Open prosp	Out-patient	46 "previously violent pts."	89%	Oral Zuc (m=35 mg/day) versus depot Zuc (m=233 mg/2 w)	1 year	Freq. viol acts scoring 2 or more on MOAS phys. agg. Subscale	Biperiden; Benzos	1. Depot Zuc assoc. w longer delay to first viol. episode 2. Depot Zuc assoc. w fewer viol. episodes in subgroup with previous freq. viol. No sig. diff.	III
Beck et al., 1997 ⁴⁴	JAAPL	Open/retros	Inpatient	20 "violent treatment resistant"	N/A	Risp 6 mg/day versus typical antipsychotics	1 year	TSBC Frequency of threats, assaults, serious property destruct	NR	No sig. diff.	III
Caspi et al., 2001 ^{37a}	Int Clin PP	RCT/crossover	Inpatient	30 "at least 4 major agg. episodes... within 2 mos."	76.6%	Adjunct PIN 15 mg/day versus adj placebo	20 weeks	OAS	Diaz; CBZ; biperiden	PIN assoc. w sig. ↓: 1. # and severity of agg. Incidents twd. other persons 2. # agg. and severity of agg. incid. twd. objects.	III
Citrome et al., 2007 ⁴⁵	Int Clin PP	RCT ^b	Inpatient	33 "who also exhibited... poor impulse control, agg. Bhv. And/or hostility	61%	Risp. 4-6 mg/day versus Risp+Adj. VPA (50-100 µg/ml)	8 weeks	OAS BDHI BIS PANSS HI	Lor; Benztr	No sig. diff. on OAS, PANSS HI, BIS, or BDHI	III
Feldman, 1982 ⁴⁶	J Clin PP	Open prosp	Inpatient	18 "hostile and aggressive"	83.3%	Before and after Lox 50-150 mg/d	10 days	BRPS H/S	Antip	Lox assoc. w sig. ↓ BRPS H/S	III
Krakowski, et al., 2006 ⁴⁰	Arch Gen Psych	RCT	Inpatient	110 "confirmed episode of phys. assault + persistence of agg."	63.6%	Cloz 200-800 mg/day versus Olan 10-35 mg/day versus HAL 10-30 mg/day	12 weeks	MOAS	Lor; Chloral H; Mood stabilizers; Antid; Diphenh; Benztr	1. Cloz assoc. w sig. greater ↓ MOAS versus Olan. or HAL 2. Olan assoc. w sig. greater ↓ MOAS versus HAL	III
Krakowski, et al., 2008 ^{147c}	J Clin PP	RCT	Inpatient	100 "Displayed persistent agg."		Cloz 200-800 mg/day versus Olan 10-30 mg/day versus HAL 10-30 mg/d	12 weeks	MOAS	Lor; Chloral H; Mood stabilizers; Antid; Diphenh; Benztr	1. Cloz assoc. w sig. greater ↓ MOAS versus Olan or HAL 2. Olan assoc. w sig. greater ↓ MOAS versus HAL	III
Class IV studies											
Afaq, et al., 2002 ⁸⁶	J Kor MA	retro	Inpatient	60 "violent subjects"	N/A	HAL (m=21 mg/d), or Olan (m=19 mg/d), or Risp (m=8 mg/d); w versus w/o adjunct divalproex sodium, (dose NR)	≤ 1 year	S&R	NR	No report of diff. in S&R	IV
Allan et al., 1996 ⁴⁸	JCP	RCT	Inpatient	34 "admitted b/c ... agg behv"	94%	Adj NAD 120 mg/day versus adj placebo	3 weeks	BRPS H/S	NR	No report of BRPS H/S at endpoint	IV

TABLE 5. Evidence Pertaining to the Question Whether Any Medication Will Reduce Overt Aggression or Hostility in Persons With Schizophrenia Spectrum Disorders Predisposed for Clinically Problematic Aggression (Continued)

Study and Evidence Level	Journal	Study Type	Setting	N/Selection Factor	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Alpert, et al., 1990 ⁴⁹	Psych P B	RCT	Inpatient	32 "with measurable levels of agg."	93.8	Adj NAD 80–120 mg/day versus placebo	3 weeks	1. BPRS H/S 2. NOSIE IS 3. OAS	Lithium	No report of BPRS H/S, NOSIE IS, or OAS at endpoint	IV
Buckley, et al., 1995 ^{7d}	B Am Acad PL	Pros observ	Inpatient	30 (11 violent versus 19 non-violent)		Before and after Cloz (dose NR)	12 months	S&R data compared in violent versus non-violent pts.	NR	Cloz=Larger ↓ in seclusion and restraint in "violent" subgroup	IV
Dalal et al., 1999 ^{4d}	CBMH	Pros observ	Inpatient	50 (20/50 violent)		Before and after Cloz (m=465 mg/day)	12–27 months	Violent bhv [nurses' obser]	NR	At 12 m: 16/20 in violent subgroup "less severe violent bhv."	IV
De Domenico, et al., 1999 ¹⁵⁰	IJPCP	retro	Inpatient	16 "manifest agg. bhv."	N/A	Before and after Cloz 150–400 mg/d	12 months	1. Agg acts per Wistedt Agg +Soc Dysfunc Scale 90 2. S & R data 3. need for chemical restraint	Benzos	1. Sig. ↓ in agg. acts	IV
Gobbi et al., 2006 ¹⁵¹	J Clin PP	Retro case-control	Inpatient	45 at a max security hospital for agg. or impulsive patients (4% bipolar)	N/A	Before and after adjunct Top100–300 mg/day or VPA (350–700 μmol/L) or both	24 weeks	1. OAS 2. ACES 3. Episodes of iso without seclusion 4. Episodes of therapeutic iso 5. Episodes of strict surveillance	NR	1. All rx assoc. w ↓OAS scores 2. VPA assoc. w ↓ACES 3. Top assoc. w ↓ strict surveillance 4. Neither rx impacted episodes of isolation	IV
Grinshpoon, et al., 1998 ¹⁵²	Eur Psych	Open props	Inpatient	10 "long term psychotic aggressive"	NR	Before and after Zac decanoate 200–300 mg/4 w	9 months	surveillance BPRS H/S	NR	Zac d. assoc. w sig. ↓ H/S	IV
Hakola and Laulumaa, 1982 ¹⁵³	Lancet	retro	Inpatient	8 women w "violent episodic outbursts"	N/A	Before and after adjunctive CBZ 400–800 mg/day	2 months – 11 years	violence	NR	↓ violence (no statistical measure reported)	IV
Maier, 1992 ¹⁵⁴	B Am Acad PL	Pro observ	Inpatient	25 (all agg. criminals)	76%	Before and after Cloz 300–600 mg/day	6–15 months	Release by court Transfer to less secure unit/hosp	Clon; PROF ^e	52% either D/C'd or transfer to less secure hosp.	IV
Morand, et al., 1983 ¹⁵⁵	Bio Psych	RCT/crossover	Inpatient	12 "aggressive schizophrenics"	100%	Adjunct tryptophan 4 g/day versus 8 g/day	11 weeks ^f	1. BPRS H/S 2. Ward checklist	Antipsychotics	1. Tryptophan 4 mg/d assoc. w 10% ↓ H/S 2. Either does assoc. w sig. ↓ ward incidents	IV
Okuma et al., 1989 ³⁶	Acta Psych Scand	RCT	Inpatient +Out-patient	162/subset of 94: "prominent violent or agg. Bhv."	91%	Antipsychotic+CBZ 200–1200 mg/day versus antipsychotic +placebo	4 weeks	BPRS HI	Sleeping pills; Antilp	1. No sig. diff. on H in entire group of 162 2. Impact on agg. in agg-subset NR	IV ^g
Rabinowitz, et al., 1996 ¹⁵⁶	Schiz Res	Retro	Inpatient	47 pts with some one or more incid of agg over 6 mo	N/A	Before and after Cloz 100–600 mg/day	9 months	1. Agg incidents 2. S&R data 3. BPRS HI	NR	1. Sig. ↓ in agg. incidents (only in first 3 m) 2. ↓ Restraint 3. ↓ BPRS HI	IV

TABLE 5. Evidence Pertaining to the Question Whether Any Medication Will Reduce Overt Aggression or Hostility in Persons With Schizophrenia Spectrum Disorders Prescribed for Clinically Problematic Aggression (Continued)

Study and Evidence Level	Journal	Study Type	Setting	N/Selection Factor	Percent Complete	Comparison	Duration	Outcome Measure	Concomitant Medications Permitted	Results	Class
Ratey et al., 1993 ¹⁵⁷	JCP	Retro	Inpatient	5 "severely aggressive"	N/A	Before and after Cloz (dose NR)	≤ 1 years	1. Nurses' prog. notes 2. S&R data OAS	Fluph; IMJ; Lor; Clon; VPA; NAD; Benztr Lor; Lithium; Benztr	1. Trend: 31.8% ↓ in assaults 2. Trend: ↓ S&R No persistent diff.	IV
Ritrovato et al., 1989 ¹⁵⁸	Clin Pharm	Prosp observ/crossover ^h	In-patient	7 "with aggressive behavior"	28.6%	Thioth or Meso w and w/o adjunctive NAD ^c	76 days				IV
Sorgi et al., 1986 ¹⁵⁹	AJP	retro	In-patient	7 with "chronic assaultiveness"	N/A	Before and after adjunctive NAD 40–160mg/day or PROP 160mg/day	4–20 weeks	1. Level of restriction 2. # agg. behaviors	NR	1. ↓level of restriction 2. 4/7 exhibited ">70% ↓" in assaults ⁱ	IV

^aCaspi et al., 2001 is also reported in Table 2 since this is an adjunctive tx trial.

^bRe. Citrome et al., 2007: although the study was "open labeled" the ratings were allegedly blind.

^cKrakowski et al., 2008 appears to be a redundant publication describing a subgroup of those reported in 2006.

^dBuckley, et al., 1995 and Dalal et al., 1999 are also reported in Table 1 because some of the patients in the study were nonviolent.

^eRe. Maier, 1992: Concomitant medications were only reported for subset of subjects.

^fRe. Morand et al., 1983: 2-week washout; then 4 weeks on one tx; then 1 week between txs; then 4 weeks on second tx.

^gOkuma et al., 1989 was demoted because no separate report of impact of medications on aggression in the aggressive subset of 94.

^hRe. Ritrovato, et al., 1989: A-B-A design: placebo, active tx, placebo.

ⁱRe. Sorgi et al., 1986: no report of test of significance.

pharmacological interventions to reduce anger, hostility, aggression, and violence among persons with schizophrenia spectrum disorders.

That having been said, at least three categories of limitations mandate caution in the interpretation of the results. First, our investigation is not the most comprehensive possible review. We elected to employ multiple search strategies and sieve multiple databases. Yet we did not pursue 1) foreign language literature, 2) abstracts, 3) gray literature, or 4) findings in the possession of the original scholars that they may not have reported. Nor did we request original data with a view toward reanalysis (e.g., controlling for concomitant administration of other psychotropic medications) or reconciliation of methodology to facilitate meta-analysis. The 804 citations and 92 qualifying publications we identified are, thus, a subset of the extant scholarly record.

Second, a limited volume of high-quality RCTs have been completed that rigorously address the efficacy of pharmacological agents for the management of aggression, especially among persons with SSDs. The limited number of publications satisfying all criteria for the highest ratings of scientific quality is perhaps a product of multiple challenges. One could fault past studies for methodological weaknesses, but we prefer to emphasize the ambitious efforts that clinical scholars have made to gather useful data under the most trying circumstances. For instance, although concomitant administration of agents such as sedative-hypnotics, antidepressants, and anxiolytics introduces a problematic confound, it is understandable that clinical researchers typically continued administering such habitual agents to hospitalized (and presumably quite ill) persons suffering from SSDs. Similarly, although dedicated aggression scholars strongly encourage distinctions between types of aggression and ideal clinical studies would investigate the efficacy of an agent on a specific aggression type, clinical psychiatric researchers are not usually trained to discriminate these nosological nuances, classification is not always easy, and it is understandable that the studies on acutely mentally ill persons may include a spectrum of semiologies under the rubric "aggression." Ideal studies might also have tested inter-rater reliability for measures of aggression/hostility, stratified results according to subtypes of SSDs, controlled for nonspecific sedative effects, and attempted to control for many possible mediating or moderating variables such as age, age of onset, socioeconomic background, education, etc. The methodological imperfections across this literature mandate considerable caution in

generalizing from the results. Yet, we honor the extraordinary efforts of those who have contributed studies in this field to date—especially the elite cohort of scholars who have done most of the heavy lifting.

As Citrome¹⁶² pointed out, multiple structural barriers frustrate well-meaning attempts to study this issue. Definitions of aggression vary, both in the literature and according to institutional culture. Aggressive events are relatively rare, such that researchers are either obliged to default to the proxy measure, hostility, or to conduct very large trials with long baselines and study periods. There is a risk of selection bias because hostile patients are perhaps less likely to agree to (or be competent to) sign informed consents. Few clinics or hospitals are equipped to treat the most aggressive psychiatric patients. Outpatient aggression is difficult to monitor or quantify. Compliance issues frustrate both the effort to help and to study these patients. Studies that might otherwise have qualified for Class I status were demoted because of rates of completion below 80%, yet low completion rates are typical in RCTs of treatments for schizophrenia.¹⁶³ Equally problematic: pharmaceutical companies may not be motivated to attempt demonstrating that their proprietary agents qualify for FDA approval for the indication of controlling aggression. This hugely limits the potential research funding pool. Considering these challenges, it is impressive that so many investigators have carried their studies from conceptualization through publication.

Third, and perhaps the most important caveat regarding the clinical application of our findings, because of the fact that the available data were derived from studies on clinically heterogeneous subject pools, it is not possible to predict to what extent our conclusions will apply to individual patients. Again, factors including age, age of onset, multiple demographic factors, diagnostic subtype, severity, relative predominance of positive versus negative symptoms—in addition to genetic and epigenetic variation—plausibly influence the likelihood that a given treatment will benefit a given patient, yet it would require much larger studies to include representative samples of the broad spectrum of SSDs, meaningfully control for the many potential confounds, and then statistically control for multiple comparisons.

For practical reasons, some studies confined recruitment to patients previously shown to be responsive to antipsychotic medications, whereas others only recruited treatment resistant patients—each type of study applying various definitions of responsiveness or treatment

resistance. Few studies employed formal typologies of aggression, such that reported measures of efficacy usually represents an average benefit (or lack thereof) in a mixed population of patients (see e.g.,^{17,164}), among which might be found patients exhibiting such diverse problems as 1) indiscriminate agitation, 2) impulsive aggression, 3) persistence of conduct disorder, 4) psychopathy-associated instrumental aggression, 5) chronic hostility, 6) aggression precipitated by substance abuse, 7) violence in response to specific threatening or control-override delusions, or 8) any combination of the above. It is possible (one ventures to say probable) that the efficacy of any agent is different among persons with different developmental and neurobiological pathways to, and types of, aggression.

Evidence exists that a subset of persons with SSDs exhibits cognitive impairment, variably associated with motor skills impairment, eye movement abnormalities, and cerebral atrophy—a syndrome sometimes discussed under the rubric of “deficit schizophrenia.”^{165–168} Aggression among those with SSDs who exhibit neurological deficits may have a different neurobiological basis than among those who seem neurologically intact¹⁶⁹ and, thus, respond to different agents. Aggression among actively psychotic persons may have different determinants and medication responsiveness than aggression among persons with SSDs whose psychosis is controlled.¹³ Aggression among persons with SSDs and comorbid antisocial traits is possibly associated with somewhat different neurobiological correlates¹⁷⁰ and may require a significantly different therapeutic approach (see¹⁷¹). Aggression successfully managed by a medication among inpatients may not be efficacious among outpatients.²⁹ Gender or hormonal status may impact both the phenomenology and the responsiveness of SSD-related aggression.¹⁷² Some evidence suggests that compliance is a key factor in determining the efficacy of medications for the control of aggression in SSDs.^{173,174} Indeed, one paper in our review¹⁴³ explicitly demonstrated an association between compliance and efficacy. However, measures of compliance were not reported in the overwhelming majority of outpatient trials, confounding an attempt to determine whether relative efficacy was more plausibly attributable to the type of medication versus the rate of adherence.

An additional limiting factor seemed to be the rigidity of the standard method for classification of evidence. In many cases, reports were demoted from Class I to Class II only because the rate of completion was below 80%—an historically hard-to-reach criterion in studies of persons

with schizophrenia. In some cases (e.g.⁴⁶), reviewers felt constrained by the strict adherence to one or more rules that required demotion from Class II, despite seemingly strong evidence of efficacy. In some cases (e.g.⁴⁸), reviewers felt compelled to demote a report because some simple piece of information was missing, perhaps due to oversight that could perhaps have been readily overcome by the investigators. In essence, coauthors of the present manuscript expressed concern that a strict application of the AAN classification scheme—e.g., requiring for Class I that only the impact on primary outcome measures be considered and that at least 80% of enrolled subjects completed the study—might sometimes be at odds with the realities of clinical psychiatric research, and sometimes lead to a failure to capitalize on valuable data.

One difficult-to-quantify trend seemed to emerge from this review: several investigators noted that most or all of the benefit for the management of hostility or aggression was apparent early in the course of the trial. In Chiles et al.,⁸⁷ for example, all the improvement apparently occurred between weeks 2 and 4 of treatment. In Dalal et al.⁹⁴ the reduction in violence occurred only in the early phase. One might tentatively conclude that, while the anti-aggressive benefit may not emerge immediately, an empirical trial of perhaps one month should be sufficient to gauge the likelihood of response to an antipsychotic medication. Moreover, some evidence suggests the possibility that mood stabilizers may produce whatever benefit they will within one week.¹³⁸ If confirmed, this suggestion would both clarify the required duration of future short-term inpatient studies and conceivably enhance the clinical appeal of agents shown to have a quicker onset of efficacy.

The association between SSDs, aggression, and substance abuse deserves special comment. Evidence shows that person with schizophrenia who also exhibit alcohol dependence or other substance abuse are significantly more likely to commit violent acts (e.g., see references^{2,6,20,175}). It is possible that comorbid stimulant abuse is especially dangerous.¹⁷⁶ Yet, the overwhelming majority of the empirical research on the efficacy of interventions fails to 1) report having assessed substance abuse systematically and 2) fail to stratify results between patients with and without comorbid substance abuse. As challenging as the research would be, one must urge accounting for dual diagnosis in future trials.

Considering the manifold barriers to definitive scholarship in this field, it would be imprudent to propose a unitary pharmacological algorithm. It would require

a massive multicenter RCT, stratifying for multiple demographic, clinical, and biological variables, to provide practice parameters meeting the new Institute of Medicine requirements for the development of a practice parameter,¹⁷⁷ let alone to provide reliable recommendations regarding the optimum intervention for a given patient. That having been said, based on a rigorous analysis of the available data, the authors provisionally recommend that clinicians consider a trial of paliperidone for the management of persistent hostility among persons with SSDs.

Aggression and violence committed by persons with SSDs causes both personal and public tragedies. Several recent notable mass murders have been attributed to persons suspected of having schizophrenia.^{178–181} We cannot opine regarding any individual case, especially when diagnostic information is only available from the popular media. However, given the multiplicity of public and private tragedies attributable to schizophrenia-related aggression, the neuropsychiatric community may wish to rethink the research strategy most likely to generate clinically useful results.

Based on the present review—and acknowledging the extraordinary practical barriers to funding and conducting a definitive trial—we propose that a state-of-the-art study of neuropharmacological management of aggressive and violent behavior among persons with SSDs would ideally contain the following elements:

1. To mitigate the confounding variable of diagnostic heterogeneity, all subjects should share a single, relatively unitary DSM diagnosis, such as Schizophrenia.
2. The study should control for or exclude subjects with concomitant psychopathy or antisocial traits.
3. An ideal research design might begin with an inpatient phase to (a) permit comprehensive baseline assessment, (b) rule out conflating neurological/medical issues, and (c) achieve stabilization under conditions of known compliance. However, given the relatively high rate of noncompliance with drug therapy among outpatients with schizophrenia (e.g.¹⁸²), and grossly different situational factors in in- versus out-patient settings in regard to potential triggers of or opportunities for aggression, measures of efficacy based on inpatient studies cannot be presumed to have ecological validity. The efficacy of an agent for reducing the risk of community aggression can best be tested via follow-on outpatient studies.
4. Given the intermittent nature of overt aggressive episodes, a 2- to 3-year duration should be required.

5. Subjects should be able to tolerate treatment with a single psychotropic medication. That is, either *no* concomitant medications should be administered, or perhaps all patients should receive the same low dose of an anti-Parkinsonian agent.
6. To mitigate the serious confounding factor of compliance, antipsychotics should be administered in depot form.
7. Given preliminary evidence of the efficacy of antipsychotic medications and the impracticality of a placebo controlled study, the design should either (a) compare of two or more depot antipsychotic medications or (b) assess the efficacy of an adjunctive agent among subjects all of whom are receiving the same depot antipsychotic.
8. The design should control for nonspecific sedation.
9. To significantly enhance the validity of measurement and to help control for the heterogeneity of type of aggression, none of the items or combinations of items from the PANSS/BPRS should serve as the independent variable. Instead, investigator should ideally employ at least two normed, validated, reliable measures of

aggression.¹⁸³ A promising design would perhaps combine an established self-rated instrument such as the Aggression Questionnaire¹⁸⁴ with an observer-rated instrument that can be adapted for outpatient use such as the Social Dysfunction and Aggression Scale⁷⁷ or a recent revision of the OAS that offers improved assessment of precipitants, the Overt Aggression Scale—Modified for Neurorehabilitation.¹⁸⁵

In the meantime, one is obliged to synthesize what is known, identify the research gaps and the most promising interventions, and utilize the limited available knowledge in clinical practice while working toward a better understanding of the bio-psycho-social determinants of SSD-related aggression.

The authors report no financial relationships with commercial interests.

The authors thank Janice Adelman, Ph.D., Claremont Graduate University; Patricia Erwin, M.L.S., Mayo Clinic Library; and Evans Whittaker, M.D., Ph.D., Norris Medical Library.

References

1. Swanson JW: Mental disorder, substance abuse, and community violence: An epidemiological approach, in *Violence and mental disorder: Developments in risk assessment*. Edited by Monahan J, Steadman HJ. Chicago, University of Chicago Press, 1994, pp 101–136
2. Tiihonen J, Isohanni M, Räsänen P, et al: Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort. *Am J Psychiatry* 1997; 154:840–845
3. Volavka J, Laska E, Baker S, et al: History of violent behavior and schizophrenia in different cultures. Analyses based on the WHO study on determinants of outcome of severe mental disorders. *Br J Psychiatry* 1997; 171:9–14
4. Eronen M, Angermeyer MC, Schulze B: The psychiatric epidemiology of violent behaviour. *Soc Psychiatry Psychiatr Epidemiol* 1998; 33(Suppl 1):S13–S23
5. Brennan PA, Mednick SA, Hodgins S: Major mental disorders and criminal violence in a Danish birth cohort. *Arch Gen Psychiatry* 2000; 57:494–500
6. Walsh E, Buchanan A, Fahy T: Violence and schizophrenia: examining the evidence. *Br J Psychiatry* 2002; 180:490–495
7. Wallace C, Mullen PE, Burgess P: Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. *Am J Psychiatry* 2004; 161:716–727
8. Hodgins S, Alderton J, Cree A, et al: Aggressive behaviour, victimization and crime among severely mentally ill patients requiring hospitalisation. *Br J Psychiatry* 2007; 191:343–350
9. Hodgins S: Violent behaviour among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention. *Philos Trans R Soc Lond B Biol Sci* 2008; 363:2505–2518
10. Arseneault L, Moffitt TE, Caspi A, et al: Mental disorders and violence in a total birth cohort: results from the Dunedin Study. *Arch Gen Psychiatry* 2000; 57:979–986
11. Hodgins S, Tiihonen J, Ross D: The consequences of conduct disorder for males who develop schizophrenia: associations with criminality, aggressive behavior, substance use, and psychiatric services. *Schizophr Res* 2005; 78:323–335
12. Benezech M, Bourgeois M, Yesavage J: Violence in the mentally ill. A study of 547 patients at a French hospital for the criminally insane. *J Nerv Ment Dis* 1980; 168:698–700
13. Swanson JW, Swartz MS, Van Dorn RA, et al: A national study of violent behavior in persons with schizophrenia. *Arch Gen Psychiatry* 2006; 63:490–499
14. McHugo GJ, Ackerson TH, Alterman AI: Antisocial personality, psychopathy, and violence in persons with dual disorders. *Crim Justice Behav* 2005; 32:452–476
15. Schug RA, Raine A: Comparative meta-analyses of neuropsychological functioning in antisocial schizophrenic persons. *Clin Psychol Rev* 2009; 29:230–242
16. Bo S, Abu-Akel A, Kongerslev M, et al: Risk factors for violence among patients with schizophrenia. *Clin Psychol Rev* 2011; 31:711–726
17. Volavka J, Citrome L: Pathways to aggression in schizophrenia affect results of treatment. *Schizophr Bull* 2011; 37:921–929
18. Rice ME, Harris GT: Psychopathy, schizophrenia, alcohol abuse, and violent recidivism. *Int J Law Psychiatry* 1995; 18: 333–342
19. Scott H, Johnson S, Menezes P, et al: Substance misuse and risk of aggression and offending among the severely mentally ill. *Br J Psychiatry* 1998; 172:345–350
20. Soyka M: Substance misuse, psychiatric disorder and violent and disturbed behaviour. *Br J Psychiatry* 2000; 176:345–350

21. Boles SM, Johnson PB: Violence among comorbid and non-comorbid severely mentally ill adults: a pilot study. *Subst Abus* 2001; 22:167–173
22. Tengström A, Hodgins S, Grann M, et al: Schizophrenia and criminal offending: the role of psychopathy and substance misuse. *Crim Justice Behav* 2004; 31:1–25
23. McGregor K, Castle D, Dolan M: Schizophrenia spectrum disorders, substance misuse, and the four-facet model of psychopathy: the relationship to violence. *Schizophr Res* 2012; 136:116–121
24. Asnis GM, Kaplan ML, Hundorfean G, et al: Violence and homicidal behaviors in psychiatric disorders. *Psychiatr Clin North Am* 1997; 20:405–425
25. Clark T, Rowe R: Violence, stigma and psychiatric diagnosis: the effects of a history of violence on psychiatric diagnosis. *Psychiatr Bull* 2006; 30:254–256
26. Solomon PL, Cavanaugh MM, Gelles RJ: Family violence among adults with severe mental illness: a neglected area of research. *Trauma Violence Abuse* 2005; 6:40–54
27. Link BG, Cullen FT, Frank J, et al: The social rejection of former mental patients: understanding why labels matter. *Am J Sociol* 1987; 92:1461–1500
28. Crisp A, Gelder M, Goddard E, et al: Stigmatization of people with mental illnesses: a follow-up study within the Changing Minds campaign of the Royal College of Psychiatrists. *World Psychiatry* 2005; 4:106–113
29. Arboleda-Flórez J, Holley H, Crisanti A: Understanding causal paths between mental illness and violence. *Soc Psychiatry Psychiatr Epidemiol* 1998; 33(Suppl 1):S38–S46
30. Hiday VA: Putting community risk in perspective: a look at correlations, causes and controls. *Int J Law Psychiatry* 2006; 29:316–331
31. Erb M, Hodgins S, Freese R, et al: Homicide and schizophrenia: maybe treatment does have a preventive effect. *Crim Behav Ment Health* 2001; 11:6–26
32. Krakowski MI, Kunz M, Czobor P, et al: Long-term high-dose neuroleptic treatment: who gets it and why? *Hosp Community Psychiatry* 1993; 44:640–644
33. Brieden T, Ujeyl M, Naber D: Psychopharmacological treatment of aggression in schizophrenic patients. *Pharmacopsychiatry* 2002; 35:83–89
34. Czobor P, Volavka J, Meibach RC: Effect of risperidone on hostility in schizophrenia. *J Clin Psychopharmacol* 1995; 15: 243–249
35. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. *J Clin Psychiatry* 1997; 58:538–546
36. Okuma T, Yamashita I, Takahashi R, et al: A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. *Acta Psychiatr Scand* 1989; 80:250–259
37. Vartiainen H, Tihiainen J, Putkonen A, et al: Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. *Acta Psychiatr Scand* 1995; 91:348–351
38. Topiwala A, Fazel S: The pharmacological management of violence in schizophrenia: a structured review. *Expert Rev Neurother* 2011; 11:53–63
39. Buckley P, Citrome L, Nichita C, et al: Psychopharmacology of aggression in schizophrenia. *Schizophr Bull* 2011; 37:930–936
40. Krakowski MI, Czobor P, Citrome L, et al: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. *Arch Gen Psychiatry* 2006; 63:622–629
41. Allen MH, Currier GW, Carpenter D, et al: Expert Consensus Panel for Behavioral Emergencies 2005: The expert consensus guideline series. Treatment of behavioral emergencies 2005. *J Psychiatr Pract* 2005; 11(Suppl 1):5–108, quiz 110–112
42. Buchanan RW, Kreyenbuhl J, Kelly DL, et al: Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull* 2010; 36:71–93
43. Citrome L, Volavka J, Czobor P, et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. *Psychiatr Serv* 2001; 52:1510–1514
44. Conley RR, Kelly DL, Richardson CM, et al: The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. *J Clin Psychopharmacol* 2003; 23:668–671
45. Volavka J, Czobor P, Nolan K, et al: Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. *J Clin Psychopharmacol* 2004; 24:225–228
46. Swanson JW, Swartz MS, Van Dorn RA, et al: CATIE investigators: Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. *Br J Psychiatry* 2008; 193:37–43
47. Marder SR, Glynn SM, Wirshing WC, et al: Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. *Am J Psychiatry* 2003; 160:1405–1412
48. Buckley PF: Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. *Curr Med Res Opin* 2004; 20:1357–1363
49. Volavka J, Czobor P, Citrome L, et al: Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. *J Clin Psychiatry* 2005; 66:1362–1366
50. Gaebel W, Riesbeck M, Wölwer W, et al: German Study Group on First-Episode Schizophrenia: Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. *J Clin Psychiatry* 2007; 68:1763–1774
51. Kahn RS, Schulz SC, Palazov VD, et al: Study 132 Investigators: Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007; 68:832–842
52. Kane J, Canas F, Kramer M, et al: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. *Schizophr Res* 2007; 90:147–161
53. Higgins JPT, Green S: *Cochrane handbook for systematic reviews of interventions*. Chichester, UK, Wiley-Blackwell, 2008
54. Davidson M, Emsley R, Kramer M, et al: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. *Schizophr Res* 2007; 93:117–130
55. Marder SR, Kramer M, Ford L, et al: Efficacy and safety of paliperidone extended-release tablets: results of a 6-week,

- randomized, placebo-controlled study. *Biol Psychiatry* 2007; 62:1363–1370
56. D'Agostino RB Sr, Massaro JM, Sullivan LM: Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. *Stat Med* 2003; 22:169–186
 57. Buckley P, Bartell J, Donenwirth K, et al: Violence and schizophrenia: clozapine as a specific antiaggressive agent. *Bull Am Acad Psychiatry Law* 1995; 23:607–611
 58. French J, Gronseth G: Lost in a jungle of evidence: we need a compass. *Neurology* 2008; 71:1634–1638
 59. Gronseth G, French J: Practice parameters and technology assessments: what they are, what they are not, and why you should care. *Neurology* 2008; 71:1639–1643
 60. Gross RA, Johnston KC: Levels of evidence: Taking Neurology to the next level. *Neurology* 2009; 72:8–10
 61. Yudofsky SC, Silver JM, Jackson W, et al: The Overt Aggression Scale for the objective rating of verbal and physical aggression. *Am J Psychiatry* 1986; 143:35–39
 62. Sorgi P, Ratey J, Knodler DW, et al: Rating aggression in the clinical 6 setting, a retrospective adaptation of the overt aggression scale: preliminary results. *J Neuropsychiatry* 1991; 3: 52–56
 63. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull* 1987; 13:261–276
 64. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. *Psychol Rep* 1962; 10:799–812
 65. Guy W: ECDEU Assessment Manual for Psychopharmacology —Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp 218–222
 66. Hedlund JL, Vieweg MS: The Brief Psychiatric Rating Scale: A comprehensive review. *J Operat Psychiatry* 1980; 11:48–65
 67. Kay SR, Sevy S: Pyramidal model of schizophrenia. *Schizophr Bull* 1990; 16:537–545
 68. Peuskens J: PANSS in international multicenter trials, in the Proceedings of the First International Risperidone Investigator Meeting, Paris, 1992
 69. Bell MD, Lysaker PH, Beam-Goulet JL, et al: Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale. *Psychiatry Res* 1994; 52:295–303
 70. Casey DE, Daniel DG, Wassef AA, et al: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. *Neuropsychopharmacol* 2003; 28:182–192
 71. Behdani F, Hebrani P, Nejad MM, et al: Adjunctive estrogen treatment in women with chronic schizophrenia admitted in Hejazi and Ibn-e-Sina. *Eur Neuropsychopharmacol* 2008; 18:S390
 72. Farzin D, Hosseini SH, Shafaat A, et al: A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia. *Iran J Med Sci* 2005; 30:59–62
 73. Buss AH, Durkee A: An inventory for assessing different kinds of hostility. *J Consult Psychol* 1957; 21:343–349
 74. Plutchik R, Van Praag HM: The measurement of suicidality, aggressivity and impulsivity. *Prog Neuropsychopharmacol Biol Psychiatry* 1989; 13(Suppl):S23–S34
 75. Honigfeld G, Klett CJ: The Nurse's Observation Scale for Inpatient Evaluation (NOSIE): a new scale for measuring improvement in chronic schizophrenia. *J Clin Psychol* 1965; 21: 65–71
 76. Honigfeld DG: NOSIE: History and current status of its use in pharmacopsychiatric research, in *Modern problems in pharmacopsychiatry: psychological measurement*. Edited by Bichot P. Basel, Karger, 1973, p 238ff.
 77. Wistedt B, Rasmussen A, Pedersen L, et al: The development of an observer-scale for measuring social dysfunction and aggression. *Pharmacopsychiatry* 1990; 23:249–252
 78. Monahan J, Steadman HJ (ed): *Violence and mental disorder: developments in risk assessment*. Chicago, University of Chicago Press, 1994
 79. Monahan J, Steadman HJ, Silver E, et al: *Rethinking risk assessment: The MacArthur study of mental disorder and violence*. New York, Oxford University Press, 2001
 80. Barratt ES: Impulsiveness subtraits: arousal and information processing, in *Motivation, emotion, and personality*. Edited by Spence JT, Izard CE. Washington, American Psychological Association, 1985, pp 39–56
 81. Patton JH, Stanford MS, Barratt ES: Factor structure of the Barratt impulsiveness scale. *J Clin Psychol* 1995; 51:768–774
 82. Morosini PL, Magliano L, Brambilla L, et al: Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. *Acta Psychiatr Scand* 2000; 101:323–329
 83. Gagnon D, Adriaenssen I, Nasrallah H, et al: Reliability, validity and sensitivity to change of the personal and social performance scale in patients with stable schizophrenia. *Int J Neuropsychopharmacol* 2006; 9(Suppl. 1):S288
 84. Wittenborn JR, Holzberg JD, Simon B: Symptom correlates for descriptive diagnosis. *Genet Psychol Monogr* 1953; 47:237–302
 85. Spielberger CD, Barker L, Russell S, et al: Preliminary manual for personality inventory (STPI). Tampa, FL, University of South Florida, 1979
 86. Afaq I, Riaz J, Sedky K, et al: Divalproex as a calmate adjunct for aggressive schizophrenic patients. *J Ky Med Assoc* 2002; 100:17–22
 87. Chiles JA, Davidson P, McBride D: Effects of clozapine on use of seclusion and restraint at a state hospital. *Hosp Community Psychiatry* 1994; 45:269–271
 88. Gerlach J, Thorsen K, Munkvad I: Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial. *Pharmakopsychiatr Neuropsychopharmacol* 1975; 8:51–56
 89. Swanson JW, Swartz MS, Elbogen EB: Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. *Schizophr Bull* 2004; 30:3–20
 90. Spivak B, Shabash E, Sheitman B, et al: The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, non-randomized, 6-month study. *J Clin Psychiatry* 2003; 64:755–760
 91. Stabenau JR, Grinols DR: A double-blind comparison of thioridazine and chlorpromazine: a study of the treatment of recently hospitalized and acutely disturbed psychiatric patients. *Psychiatr Q* 1964; 38:42–63

92. Bitter I, Czobor P, Dossenbach M, et al: Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). *Eur Psychiatry* 2005; 20:403–408
93. Carney MWP: A 5-year follow-up study of chronic schizophrenics treated with clopenthixol decanoate. *Pharmatherapeutica* 1984; 4:57–63
94. Dalal B, Larkin E, Leese M, et al: Clozapine treatment of long-standing schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital. *Crim Behav Ment Health* 1999; 9:168–178
95. Kuoppasalmi K, Rimón R, Naukkarinen I, et al: Clozapine decreases the level of anxiety and aggressive behavior in patients with therapy-refractory schizophrenia. *Psychiatr Fenn* 1993; 24:153–162
96. Mallya AR, Roos PD, Roebuck-Colgan K: Restraint, seclusion, and clozapine. *J Clin Psychiatry* 1992; 53:395–397
97. Menditto AA, Beck NC, Stuve P, et al: Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. *Psychiatr Serv* 1996; 47:46–51
98. Spivak B, Mester R, Wittenberg N, et al: Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. *Clin Neuropharmacol* 1997; 20:442–446
99. Spivak B, Roitman S, Vered Y, et al: Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. *Clin Neuropharmacol* 1998; 21:245–250
100. Swanson JW, Swartz MS, Elbogen EB, et al: Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. *J Clin Psychiatry* 2004; 65:1666–1673
101. Wilson WH: Clinical review of clozapine treatment in a state hospital. *Hosp Community Psychiatry* 1992; 43:700–703
102. Wilson WH, Claussen AM: 18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital. *Psychiatr Serv* 1995; 46:386–389
103. Borison RL, Arvanitis LA, Miller BG; U.S. SEROQUEL Study Group: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. *J Clin Psychopharmacol* 1996; 16:158–169
104. Canuso CM, Dirks B, Carothers J, et al: Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. *Am J Psychiatry* 2009; 166:691–701
105. Canuso CM, Turkoz I, Sheehan JJ, et al: Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. *J Affect Disord* 2010; 120:193–199
106. Corrigán MH, Gallen CC, Bonura ML, et al; Sonepiprazole Study Group: Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. *Biol Psychiatry* 2004; 55:445–451
107. Meltzer HY, Bobo WV, Nuamah IF, et al: Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. *J Clin Psychiatry* 2008; 69: 817–829
108. Chengappa KNR, Goldstein JM, Greenwood M, et al: A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. *Clin Ther* 2003; 25:530–541
109. Aleman A, Kahn RS: Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. *Eur Neuropsychopharmacol* 2001; 11:289–293
110. Kane JM, Mackle M, Snow-Adami L, et al: A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. *J Clin Psychiatry* 2011; 72:349–355
111. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. *Am J Psychiatry* 1994; 151:825–835
112. Simopoulos AM, Pinto A, Uhlenhuth EH, et al: Diphenylhydantoin effectiveness in the treatment of chronic schizophrenics. A double-blind controlled study with a placebo. *Arch Gen Psychiatry* 1974; 30:106–111
113. Singer K, Lam CM: Evaluation of leponex (Clozapine) in schizophrenia with acute symptomatology. *J Int Med Res* 1973; 1:627–629
114. Min SK, Rhee CS, Kim C-E, et al: Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. *Yonsei Med J* 1993; 34:179–190
115. Niskanen P, Ahté K, Jasari J, et al: Results of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. *Psychiatr Fenn* 1974; 34:307–313
116. Seth S, Mahal AS, Kumar KA: A double-blind comparative trial of loxapine and trifluoperazine in chronic schizophrenic patients. *Curr Ther Res* 1979; 25:320–329
117. Vyas BK, Kalla V: A six-month double-blind comparison of loxapine succinate and chlorpromazine in chronic schizophrenic patients. *Curr Ther Res Clin Exp* 1980; 28:16–30
118. Abuzzahab FS Sr, Zimmerman RL: Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia. *J Clin Psychiatry* 1982; 43:105–110
119. Claghorn J, Honigfeld G, Abuzzahab FS Sr, et al: The risks and benefits of clozapine versus chlorpromazine. *J Clin Psychopharmacol* 1987; 7:377–384
120. Høyberg OJ, Fensbo C, Remvig J, et al: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. *Acta Psychiatr Scand* 1993; 88:395–402
121. Kane JM, Marder SR, Schooler NR, et al: Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. *Arch Gen Psychiatry* 2001; 58:965–972
122. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. *Arch Gen Psychiatry* 1991; 48:739–745
123. Müller MJ, Wetzel H, Eich F-X, et al; Amisulpride Study Group: Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. *J Clin Psychopharmacol* 2002; 22:554–560
124. Peuskens J; Risperidone Study Group: Risperidone in the treatment of patients with chronic schizophrenia:

- a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. *Br J Psychiatry* 1995; 166:712–726, discussion 727–733
125. Wang X, Savage R, Borisov A, et al: Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. *J Psychiatr Res* 2006; 40:669–676
 126. Arango C, Breier A, McMahon R, et al: The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. *Am J Psychiatry* 2003; 160:1421–1427
 127. Ebrahim GM, Gibler B, Gacono CB, et al: Patient response to clozapine in a forensic psychiatric hospital. *Hosp Community Psychiatry* 1994; 45:271–273
 128. Herman M: Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital. *Aust N Z J Ment Health Nurs* 1997; 6:129–133
 129. Levinson DF, Singh H, Simpson GM: Timing of acute clinical response to fluphenazine. *Br J Psychiatry* 1992; 160:365–371
 130. Mann K, Bartels M, Bauer H, et al: Amisulpride—an open clinical study of a new benzamide in schizophrenic patients. *Pharmacopsychiatry* 1984; 17:111–115
 131. Volavka J, Zito JM, Vitrai J, et al: Clozapine effects on hostility and aggression in schizophrenia. *J Clin Psychopharmacol* 1993; 13:287–289
 132. Maoz G, Stein D, Meged S, et al: The antiaggressive action of combined haloperidol-propranolol treatment in schizophrenia. *Eur Psychol* 2000; 5:312–325
 133. Pugh CR, Steinert J, Priest RG: Propranolol in schizophrenia: a double blind, placebo controlled trial of propranolol as an adjunct to neuroleptic medication. *Br J Psychiatry* 1983; 143: 151–155
 134. Strous RD, Ritsner MS, Adler S, et al: Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. *Eur Neuropsychopharmacol* 2009; 19:14–22
 135. Omrani V, Amel AK, Amanat S: Sodium valproate as an adjunctive drug in treatment of schizophrenia. *Iran J Psychiatry Behav Sci* 2007; 1:12–15
 136. Yorkston NJ, Zaki SA, Pitcher DR, et al: Propranolol as an adjunct to the treatment of schizophrenia. *Lancet* 1977; 2:575–578
 137. Caspi N, Modai I, Barak P, et al: Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. *Int Clin Psychopharmacol* 2001; 16:111–115
 138. Citrome L, Casey DE, Daniel DG, et al: Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. *Psychiatr Serv* 2004; 55:290–294
 139. Littrell KH, Petty RG, Hilligoss NM, et al: Valproate for hostility in schizophrenia patients. *J Clin Psychiatry* 2004; 65:134
 140. Suzana TG, Olivera Z, Gordana N, et al: Adjunctive mood stabilizing treatment: the effects on hostility and impulsivity among patients with schizophrenia. *Eur Neuropsychopharmacol* 2009; 19:S532
 141. Wassef AA, Hafiz NG, Hampton D, et al: Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. *J Clin Psychopharmacol* 2001; 21:21–26
 142. Yoshimura R, Shinkai K, Ueda N, et al: Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients. *Pharmacopsychiatry* 2007; 40:9–13
 143. Arango C, Bombín I, González-Salvador T, et al: Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. *Eur Psychiatry* 2006; 21:34–40
 144. Beck NC, Greenfield SR, Gotham H, et al: Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. *J Am Acad Psychiatry Law* 1997; 25:461–468
 145. Citrome L, Shope CB, Nolan KA, et al: Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. *Int Clin Psychopharmacol* 2007; 22:356–362
 146. Feldman HS: Loxapine succinate as initial treatment of hostile and aggressive schizophrenic criminal offenders. *J Clin Pharmacol* 1982; 22:366–370
 147. Krakowski MI, Czobor P, Nolan KA: Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. *J Clin Psychopharmacol* 2008; 28:485–493
 148. Allan ER, Alpert M, Sison CE, et al: Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. *J Clin Psychiatry* 1996; 57:455–459
 149. Alpert M, Allan ER, Citrome L, et al: A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. *Psychopharmacol Bull* 1990; 26:367–371
 150. De Domenico P, Di Rosa AE, D'agostino AA, et al: The effect of clozapine on aggressive behavior in patients with chronic schizophrenia. *Int J Psychiatry Clin Pract* 1999; 3:49–54
 151. Gobbi G, Gaudreau P-O, Leblanc N: Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. *J Clin Psychopharmacol* 2006; 26:467–473
 152. Grinshpoon A, Moskowitz M, Valevski A, et al: Zuclopenthixol, D(1)/D(2) antagonist, for treatment of chronic aggressive schizophrenia and psychotic oligophrenic patients. *Eur Psychiatry* 1998; 13:273–275
 153. Hakola HPA, Laulumaa VA: Carbamazepine in treatment of violent schizophrenics. *Lancet* 1982; 1:1358
 154. Maier GJ: The impact of clozapine on 25 forensic patients. *Bull Am Acad Psychiatry Law* 1992; 20:297–307
 155. Morand C, Young SN, Ervin FR: Clinical response of aggressive schizophrenics to oral tryptophan. *Biol Psychiatry* 1983; 18: 575–578
 156. Rabinowitz J, Avnon M, Rosenberg V: Effect of clozapine on physical and verbal aggression. *Schizophr Res* 1996; 22:249–255
 157. Ratey JJ, Leveroni C, Kilmer D, et al: The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. *J Clin Psychiatry* 1993; 54:219–223
 158. Ritrovato CA, Weber SS, Dufresne RL: Nadolol in the treatment of aggressive behavior associated with schizophrenia. *Clin Pharm* 1989; 8:132–135
 159. Sorgi PJ, Ratey JJ, Polakoff S: β -adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. *Am J Psychiatry* 1986; 143:775–776
 160. Nolan KA, Volavka J, Czobor P, et al: Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. *J Psychiatr Res* 2005; 39:109–115

161. Song H, Min SK: Aggressive behavior model in schizophrenic patients. *Psychiatry Res* 2009; 167:58–65
162. Citrome L: Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? *Expert Rev Neurother* 2009; 9:55–71
163. Khan A, Schwartz K, Redding N, et al: Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports. *Neuropsychopharmacology* 2007; 32:2422–2430
164. Volavka J, Citrome L: Heterogeneity of violence in schizophrenia and implications for long-term treatment. *Int J Clin Pract* 2008; 62:1237–1245
165. Chen EY, Kwok CL, Au JW, et al: Progressive deterioration of soft neurological signs in chronic schizophrenic patients. *Acta Psychiatr Scand* 2000; 102:342–349
166. Rosso IM, Bearden CE, Hollister JM, et al: Childhood neuromotor dysfunction in schizophrenia patients and their unaffected siblings: a prospective cohort study. *Schizophr Bull* 2000; 26:367–378
167. Bachmann S, Bottmer C, Schröder J: Neurological soft signs in first-episode schizophrenia: a follow-up study. *Am J Psychiatry* 2005; 162:2337–2343
168. Schiffman J, Sorensen HJ, Maeda J, et al: Childhood motor coordination and adult schizophrenia spectrum disorders. *Am J Psychiatry* 2009; 166:1041–1047
169. Hoptman MJ, Volavka J, Czobor P, et al: Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. *J Neuropsychiatry Clin Neurosci* 2006; 18:509–515
170. Hoptman MJ, Antonius D: Neuroimaging correlates of aggression in schizophrenia: an update. *Curr Opin Psychiatry* 2011; 24:100–106
171. Joyal CC, Putkonen A, Paavola P, et al: Characteristics and circumstances of homicidal acts committed by offenders with schizophrenia. *Psychol Med* 2004; 34:433–442
172. Teasdale B, Silver E, Monahan J: Gender, threat/control-override delusions and violence. *Law Hum Behav* 2006; 30:649–658
173. Ascher-Svanum H, Faries DE, Zhu B, et al: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. *J Clin Psychiatry* 2006; 67:453–460
174. Alia-Klein N, O'Rourke TM, Goldstein RZ, et al: Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. *Aggress Behav* 2007; 33:86–96
175. Erkiran M, Ozünelan H, Evren C, et al: Substance abuse amplifies the risk for violence in schizophrenia spectrum disorder. *Addict Behav* 2006; 31:1797–1805
176. Miles H, Johnson S, Amponsah-Afuwape S, et al: Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. *Psychiatr Serv* 2003; 54: 554–561
177. Graham R, Mancher M, Wolman DM, et al: (Eds.): for the Committee on Standards for Developing Trustworthy Clinical Practice Guidelines Board on Health Care Services: Clinical practice guidelines we can trust. Institute of Medicine of the National Academies. Washington, DC: The National Academies Press, 2011. Downloaded 8/7/12 from http://books.nap.edu/openbook.php?record_id=13058
178. Santos F: Competence was linchpin for both sides in Tucson case. *New York Times*, 8/05/2012. Downloaded 8/7/12 from <http://www.nytimes.com/2012/08/06/us/guilty-plea-expected-in-tucson-shooting-rampage.html>
179. Anonymous: Jared Lee Loughner. *The New York Times*. Updated 08/07/12. Downloaded 8/7/12 from http://topics.nytimes.com/top/reference/timestopics/people/l/jared_lee_loughner/index.html
180. Lewis M: Anders Behring Breivik delivers final tirade to bemused court. *The Guardian*, 06/22/2012. Downloaded 8/7/12 from <http://www.guardian.co.uk/world/2012/jun/22/anders-behring-breivik-final-tirade>
181. Anonymous: Anders Behring Breivik. *The New York Times*. Updated 06/22/12. Downloaded 8/7/12 from http://topics.nytimes.com/top/reference/timestopics/people/b/anders_behring_breivik/index.html
182. Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. *J Clin Psychiatry* 2009; 70(Suppl 4):1–46, quiz 47–48
183. Palmstierna T, Wistedt B: Violence in psychiatry, view-points for standardized research. *Acta Psychiatr Scand* 2000; 102:79–80
184. Buss AH, Warren WL: Aggression questionnaire manual. Los Angeles Western Psychological Services, Los Angeles, 2000
185. Alderman N, Knight C, Morgan C: Use of a modified version of the Overt Aggression Scale in the measurement and assessment of aggressive behaviours following brain injury. *Brain Inj* 1997; 11:503–523